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 As an interface between the circulatory and central nervous systems, the 
neurovascular unit is vital to the development and survival of tumors.  The 
malignant brain cancer glioblastoma multiforme (GBM) displays invasive growth 
behaviors that are major impediments to surgical resection and targeted therapies.  
Adhesion and signaling pathways that drive GBM cell invasion remain largely 
uncharacterized.  Here we have utilized human GBM cell lines, primary patient 
samples, and pre-clinical mouse models to demonstrate that integrin αvβ8 is a 
major driver of GBM cell invasion.  β8 integrin is overexpressed in many human 
GBM cells, with higher integrin expression correlating with increased invasion and 
diminished patient survival. Silencing β8 integrin in human GBM cells leads to 
impaired tumor cell invasion due to hyperactivation of the Rho GTPases Rac1 and 
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Cdc42.  β8 integrin associates with Rho GDP Dissociation Inhibitor 1 (RhoGDI1), an 
intracellular signaling effector that sequesters Rho GTPases in their inactive GDP-
bound states.  Silencing RhoGDI1 expression or uncoupling αvβ8 integrin-RhoGDI1 
protein interactions blocks GBM cell invasion due to Rho GTPase hyperactivation.  
These data reveal for the first time that αvβ8 integrin, via interactions with RhoGDI1, 
suppresses activation of Rho proteins to promote GBM cell invasiveness. Hence, 
targeting the αvβ8 integrin-RhoGDI1 signaling axis may be an effective strategy for 
blocking GBM cell invasion. 
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Introduction 
GBM Pathophysiology:  Historical and Histopathology Perspective 
 Gliomas arise from the CNS and are derived from glial cell types (astrocytes, 
oligodendrocytes, and ependymal cells) and are named accordingly as 
astrocytomas, oligodendrogliomas, ependymomas, and mixed gliomas.  Each tumor 
can differ in genetics and signaling, allowing researchers and physicians to better 
understand and exploit the pathways used by these cells(1,2).  However, tumors 
defined by histological features alone have been shown to behave differently, 
suggesting that a molecular and genetic pathology classification would be 
advantageous(1).  Additionally, in the past five years evidence has been 
accumulating that some brain tumor cells may behave similar to stem cells(3-5).  
The original nomenclature has become even more complicated as some of these 
cells have been found to transform into endothelial-like cells(6,7).  Nonetheless the 
current naming convention has remained intact with an additional classification 
system further categorized by the World Health Organization (WHO).   
 Astrocytic gliomas have been broken divided into four stages with the first 
being largely separated by 2, 3, and 4.  Stage I is characterized by their decreased 
ability to transform to a malignant state and are less invasive(7).  An example of 
these is pilocytic astrocytomas.  These less infiltrative tumors are often considered 
benign and can often be surgically resected, unlike higher stages(2).  Stage II 
tumors, such as low-grade astrocytomas, are much more diffuse beyond the 
primary tumor mass and are not surgically curable.  Stage III tumors, such as 
anaplastic astrocytomas, are increasingly more invasive and more proliferative(1).  
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Stage IV gliomas are yet more invasive, more proliferative, have increased 
vascularization, and are the most fatal.  The most common gliomas diagnosed are 
glioblastoma multiforme (GBM), a WHO stage IV tumor(1). 
 Brain tumors do not have unique symptoms with the first sign being 
headaches, blurred vision, and nausea.  As such patients and physicians do not 
often detect these tumors in their early stages.  Typically the disease has 
progressed to the latest stage with the most severe symptoms before imaging is 
conducted, where the GBM is diagnosed(1).  Because of this, most gliomas are 
diagnosed at a later stage and have worse outcomes.  So while GBMs are rare, 
they are extremely fatal, when compared to other tumors.  The typical survival time 
is 9-14 months from diagnosis(1-3).  One of the distinguishing hallmarks of GBMs is 
their invasiveness.  While a primary mass can be surgically resected, individual 
tumor cells that have invaded into the surrounding healthy tissue cannot be and 
form satellite tumors.  This makes the invasive phenotype an important property to 
understand and why it was chosen for investigation herein. 
 
Gliomagenesis: Cell Biology and Genetics 
 Neuroepithelial are stem cells that give rise to a majority of the cells in the 
CNS(6).  These neuroepithelial cells progress along different pathways to 
differentiate into multiple cell types.  As is understood in stem cell biology these 
cells typically assume two paths; (1) to asymmetrically divide to form a progenitor-
like cell and a precursor cell or (2) to form two differentiated daughter cells slightly 
more restricted than the previous.  At each stage of the subsequent divisions the 
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daughter cells gradually become a more defined cell type.  Within the past 5 years 
considerable evidence has arisen suggesting GBMs may originate from an event 
that causes the differentiated cells to revert to a stem like state, exploiting aberrant 
signaling pathways along the way(6,7).   It is therefore no surprise that many of the 
proteins and mechanisms of interest to cancer biologists are also used by the cells 
for development.  Additionally, it is likely that relationships are also shared between 
GBMs and repair pathways.  An example of this is nestin-positive reactive 
astrocytes and nestin-positive progenitors, which are known to migrate to a site of 
injury.  This example is interesting as terminal astrocytes do not express nestin, yet 
it has been detected in GBMs. 
 The genetics of GBMs has also been of interest in recent years.  One of the 
most well studied mechanisms in cancer biology involves p53, which is a 
transcriptional activator of p21, a cyclin-dependent kinase inhibitor which inhibits the 
cell cycle(4).  Additionally, p53 is able to transcriptionally activate Bax while 
inhibiting Bcl-2, which are pro-apoptotic and anti-apoptotic respectively(8-11).  
Therefore, it is easy to understand how important p53 may be in GBM development 
and progression.  Indeed evidence has accumulated that mutations in p53 are often 
found in low-grade gliomas whereas those that arise primarily often do not have p53 
mutations(12).  However, no prognostic advantage has been found with regard to 
p53 mutations in GBMs.   
 Interestingly those with functional p53 often overexpress EGFR or have 
mutated EGFR(12).  These activated mutants are thought to lend a selective 
advantage, leading to increased proliferation while reducing apoptosis.  Amplified 
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EGFR is associated with GBM and its activation has been found to influence the 
growth of both astrocytes and their precursors.  EGFR overexpression correlates 
well with high grade GBMs and has long been thought to play a critical role in the 
formation of these tumors(12).  With such influence over cell behavior it is no 
wonder this is a widely explored drug target with antibodies and small molecule 
inhibitors currently being developed(1,3,13).  Other growth factors are also of 
interest including fibroblast growth factor (FGF), platelet-derived growth factor 
(PDGF), and insulin-like growth factor (IGF); lending much credit to the importance 
of extracellular signaling taking place across the ECM(14,15).  However, as EGFR 
is the most commonly over-expressed receptor in gliomas, it is currently of the most 
interest. 
 It is also interesting that cells overexpressing mutated wild-type EGFR along 
with PTEN display the most favorable outcomes with EGFR inhibitors.  However, 
loss of PTEN in GBM patients lend them a poor prognosis and it is mutated in 
GBMs with predictions of mutation in the 20% range(2).  Wild-type PTEN has also 
been shown to rescue the mutated protein by halting proliferation.  It is also thought 
that this protein may play a role in preventing invasion by interacting with FAK.  
However this claim has not been completely substantiated in GBMs and its all the 
more reason to further investigate these pathways(16,17). 
 
Integrins: Basic Function 
 Integrin are defined by two unique chains, termed their α and β subunits.  
These obligate heterodimer receptors exist in 26 known combinations utilizing 
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eighteen α and eight β subunits. Most integrins are part of either the β1 or αv 
subfamilies, which is the breadth of this review(18).  It is easily understood that the 
combination of these subunits determine the extracellular and intracellular binding 
and signaling events.  The network of integrin-ligand interactions is vast: some 
integrins are ligand-specific while others bind many shared ligands.  This overlap 
allows for one ligand to have multiple effects on a cell through different integrins 
while also maintaining its equilibrium.  Conversely integrins are capable of inside-
out signaling, making them a medium for large amounts of communication taking 
place within the microenvironment(19).  During development this has been seen to 
regulate adhesion and migration.  However in the context of tumorigenesis within 
the brain this is expanded to include proliferation, survival, and differentiation(20).  
Additionally, within the cell all integrins discussed here are link to the actin 
intracellular microfilament network. 
 
ECM Components: Basic functions     
 The cellular environment is of great importance in GBM development and 
persistence.  Gliomas develop alongside non-neoplastic endothelial cells and 
astrocytes as well as the native extracellular matrix (ECM).  As a GBM develops it 
modifies its ECM into a niche that is further exploited by the tumor and is also a 
distinguishable fingerprint. 
 A prominent feature of integrins is their ability to connect to the ECM.  The 
ECM itself is between astrocytes and blood vessels.  Since astrocytic end-feet wrap 
around blood vessels, the integrin-ECM complex is extremely important.  Integrins 
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are able to bind extracellular ECM scaffolding proteins such as laminins and 
collagens and also bind intracellular cytoskeletal elements such as talin.  This direct 
link allows for the cell to detect its environment and heavily influences the how and 
where a cell migrates as well as communicates whether the given environment is 
suitable for growth.  Downstream, these send signals through kinases such as FAK 
and Src.  Beyond cell-ECM communication, integrins are also capable of influencing 
growth factors.  These have been known to include Epidermal growth factor (EGF), 
Fibroblast growth factors (FGF), Vascular endothelial growth factor (VEGF), 
platelet-derived growth factor (PDGF), Interleukins (ILs), and Transforming growth 
factor beta and alpha family members (TGFβ/α).  The wide influence of integrins 
also includes regulation of enzymes such at Matrix metalloproteinases (MMP) and 
tissue inhibitors of metalloproteinases (TIMP)(21-25).  These highly responsive 
elements are capable of degrading components of the ECM, influencing cell motility.  
It is through these extra and intracellular components that we understand the 
intermediary role of integrins as translators of signals and through their known 
pathological behaviors we then classify integrins as major players of tumorigenesis. 
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Various Roles of Integrins in Astrocytes: 
β1s 
 A substantial trait of GBMs is their invasiveness.  While the β1 subfamily of 
integrins in astrocytes has not been reported to play a major role in GBM growth, 
they are involved in invasion.  Integrins α2β1, α3β1, α5β1, and α6β1 have been 
seen to be over expressed in astrocytes (26, 27).  It has been found that blocking 
monoclonals against is effective at slowing cell migration in vitro(28,29, 30).  One of 
the highest expressing integrins, α3β1, has been seen to be involved in invasion 
both in-vitro and in-vivo (29,30).  This is likely occurring through stimulation by its 
laminin ligand(31,32).  While not all β1 integrin pairs have been investigated, it is 
likely that the non-invasive phenotype seen with dysfunctional β1 is attributed to 
α3β1 (29). 
 
αvs 
 Even if a primary tumor mass can be fully resected, it is likely that individual 
cells have invaded into the surrounding tissue.  These highly motile cells then spur 
secondary lesions.  The involvement of integrins here is vast with αvβ1, αvβ3, αvβ5, 
αvβ6, and αvβ8 being involved in motility and growth(33-35).  Knockout of αv, and 
thus absence of all the αv integrins, leads to severe cerebral hemorrhage and 
lethality(19).  Other than the loss of the vast signaling pathways, this situation 
eliminates the formation of any αv integrin depend focal contacts.  This is mostly 
due to the cytoplasmic portion of the β subunit being responsible for binding to the 
cytoskeletal proteins. 
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αvβ1       
 Angiopoietin-2 has been seen to act on αvβ1 to activate FAK and ERK1/2 as 
well as increase the expression of MMP2, which is of relevance to αvβ3 as 
described below (36).  However this receptor is not expressed in all GBMs (37).  
 
αvβ3       
 The integrin αvβ3 is known to have FN, VN, osteopontin, tenascin, and von 
Willebrand factor as ligands; however, the role of these within the tumor 
microenvironment has largely been unexplored.   Along with the tumor vasculature, 
αvβ3 is also known to be expressed on GBM-glial cells (38).  Following this 
observation, it has been seen that anti-αvβ3 inhibition can lead to reduced 
angiogenesis, tumor size, and invasion (39).       αvβ3 dependent GBM invasion is 
known to utilize MMP2 (40,23,41).  TGFβf2-stimulated invasion is reduced when 
either αvβ3 or MMP2 is inhibited in vitro (42).  It is also likely that tissue inhibitor of 
metalloproteinases 2 (TIMP-2) is involved with MMP2, but more work needs to be 
carried out with GBM models (43,24,44).  αvβ3 and αvβ5 are also involved with 
hypoxia(45-47).  Under hypoxic conditions they are recruited to the cell membrane.  
In addition to being activated by hypoxic condition they also communicate the 
oxygenation state of the cell by activating GSK-3β, RhoB, and FAK to stabilize HIF-
1α, implying a feedback mechanism (17).  As αvβ3 has become associated with 
motility, it is of interest that it also inhibits tumor growth when over expressed 
(40,23,41,48).  The Pieper group has also found that β3 over expression will result 
in smaller vessel size and a more hypoxic tumor.  While these phenotypes could be 
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rescued by activating Akt and VEGF pathways common in GBMs, it presents an 
interesting situation in the context of hypoxia.  Combining these data with the 
aforementioned hypoxic mechanism proposed by the Moyal group presents an 
interesting dilemma for GBM patients (17,48).  Should a group of cell in the niche be 
αvβ3 high and become hypoxic, it may be possible for the signal to amplify itself 
and spread beyond the local site.  
 
αvβ5 
 Besides being overexpressed in GBMs, αvβ5 has some interesting relations 
to αvβ3 (49,50,51).  Externally, αvβ5 is able to activate latent-TGFB1 spurring 
TGFBRI/II the pathway while the αvβ3 is only able to change latent-TGFB1 
conformation (52,53).  Also, αvβ5 has been seen internalize VN, while αvβ3 was 
dependent on αvβ5 for it to internalize VN(54).  PDGFR has also been seen to 
associate with αvβ3 but not αvβ5 in GBM samples (55).  And while these 
differences occur, internally both integrins share the GSK-3- RhoB-FAK pathway 
that stabilizes HIF-1α under hypoxic conditions (17). 
 Interestingly, while both of these integrins can bind vitronectin, αvβ5 has 
been seen to be required for in-vitro motility independent of αvβ3 (56). 
 
αvβ6      
 While αvβ6 is known to activate TGFB1 and TGFB3 in normal brain, its 
effects in GBM models have yet to be explored(57). 
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αvβ8     
 The normal brain depends on αvβ8 and its interactions with the ECM.  The 
blood vessels of mice null for αv or β8 dilate, the blood barrier is compromised, and 
the mice suffer severe hemorrhaging(18, 58).  As αv is known to form αvβ3, αvβ5, 
and αvβ8 integrin pairs, it is there for likely that the phenotype seen when αv is 
knocked out is caused by the loss of αvβ8.  The current understanding of this 
integrin is that it binds to the RGD site of its ligand LAP-TGFβ1/3.  Once bound it 
cleaves the LAP portion, leaving only the TGFβ1/3.  It is this TGFβ1/3 that is 
considered active which can then signal by binding to the TGFβRI/II receptor.  This 
receptor allows for the autophosphorylation of Smad2 and Smad3.  These are then 
transported into the nucleus by Smad4 where TGFβ target genes are up regulated.  
It is also interesting to note that when TGFβ1/3 or TGFβR2 are ablated in 
endothelial cells hemorrhaging also results that is pathologically very similar to the 
ablation of αvβ8 this has led to a model where αvβ8, TGFβ1/3, and TGFβR2 are 
involved in the same signaling pathway (Figure).  Interestingly, in both normal brain 
and GBM samples this pathway has been investigated for its role in motility (59,60).  
It has also recently been seen that αvβ8 plays a role in angiogenesis, which may be 
occurring through the negatively regulating mir-93; which leads to silencing β8 and 
an increase in tumor angiogenesis and size (61,62).  This is of great clinical 
significance because numerous attempts are being made to elucidate the 
angiogenic pathways involved in GBMs(10,63-72).  Additionally, many attempts are 
being made at targeting this hallmark of cancer(73-89).     
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Various Roles for Integrins in Endothelial Cells: 
α1β1 & α2β1 
 A distinctive hallmark of GBMs is that they are highly vascularized.  A critical 
factor in this process is the expression of β1 on endothelial cells (27,90).  As a 
subunit involved in 12 integrin pairs its importance is self evident, with α1β1, α2β1, 
α3β1, α4β1, α5β1, α6β1, and α7β1 expression known to occur on endothelial cells 
and α2β1, α4β1, and α6β1 known to be over expressed in GBM endothelial 
cells(26).  α1β1 and α2β1 have been show to promote angiogenesis in response to 
VEGF through the Erk1/Erk2 MAPK signal transduction pathway (69, 91-93).  
Antibodies directed against these integrins individually inhibited angiogenesis, in-
vivo.  Additionally, when used in combination the inhibition of these two integrins led 
to a significant reduction in tumor size and angiogenesis (91).  Interestingly, α1-null 
mice which lack the α1β1 integrin do not harbor tumors well and illustrate a 
decrease in vascularization.  Additionally MMP-7 and MMP-9 levels are elevated in 
α1-null mice, which are known to convert plasminogen into angiostatin, an inhibitor 
of angiogenesis (94-98).  Although the involvement of α2β1 has not been clearly 
elucidated, it is likely involved in growth arrest (99,100).  Upon α2β1 binding its 
laminin ligand, the ability of α5β1 to form focal adhesions is reduced.  This limits the 
ability of α5β1 to communicate its downstream signals and inhibits cell proliferation 
(100). 
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α5β1 
 α5β1 is also a major endothelial player, being primarily influenced by its 
fibronectin (FN) ligand.  α5-null teratocarcinoma are smaller and with less 
vascularization (101,102).  Additionally, α5-null embryoid body formations also have 
delayed vascular differentiation (102).  Interestingly, α5 and FN knockout mice are 
embryonic lethal and share angiogenic abnormalities(102,103,104,101).  β1- null 
mice are also embryonic lethal with similar vascular pathologies, lending credence 
to the hypothesis that the β1-null phenotypes can be attributed to the α5β1 
integrin(105).  Clinically the anti-α5β1 monoclonal Volociximab is in early trials, 
being explored as an anti-angiogenic therapy(106-113).  ATN-161, anti-angiogenic 
α5β1 targeting peptide, is in stage II head and neck clinical trials with plans for a 
glioblastoma trial (66,64,72,114).  
 
 
α3β1 & α6β1  
 Due to early lethality, limited studies have been carried out exploring α3β1.  
However, the Hodivala-Dilke group has created conditionally knocked out α3 in 
endothelial cells.  In non-brain ex-vivo and in-vivo models, loss of α3 led to larger 
tumors, more angiogenesis, and up-regulation of VEGF (65,115).  α6β1 has been 
seen to be both upregulated and activated by VEGF in human brain cells along with 
several other interesting phenomena (116-125).  Additionally, it is thought that they 
are the primary brain endothelial integrin involved in laminin adhesion (126).   
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α4β1 & α7β1  
 Integrin α7β1 knockout mice have interesting pathologies in regard to CNS 
vasculature.  The mice are embryonic lethal possibly do to severe cerebrovascular 
hemorrhaging.  Interestingly, mice that survived revealed hyperplastic and 
hypertrophic defects as well as down-regulated α5 in cerebral vasculature(127).  
While α4β1 is known to be expressed on endothelial cells, studies have been 
mostly carried out in human umbilical vein endothelial cells (HUVECs) and not of 
normal brain of GBM origin (20, 128). 
 
αvβ3 & αvβ5   
 β3 and β5 double knockout mice are viable, have no obvious vascular 
pathologies (129), yet a different story is told in the context of tumorigenesis.  αvβ3 
and αvβ5 are over expressed in  GBM endothelial cells  and while its mechanism in 
GBMs has yet to be fully elucidated, there are promising developments with strong 
evidence of c-Abl involvement (40,130-132).  Inhibition of αvβ3 and αvβ5 has been 
seen to induce endothelial apoptosis (67).  An αvβ3 inhibitor has also been see to 
have similar success in vivo with a group developing a tracer for identifying GBM 
angiogenesis (19,63). 
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Table 1.  
Integrin Structural ECM 
Ligands 
Soluble 
Ligand 
Expresssion  
(Cell Type) 
Citation 
αvβ1            F           V                            TGFβ A  (133), (134) 
αvβ3            F    O    V    
T    W        
MMP2 EA (135), (54) 
αvβ5                         V                     TGFβ A E (59), (134), 
(20), (54) 
αvβ6            F                  
T                  
TGFβ A (133), 
αvβ8 L   C    F                                TGFβ A (59), (134) 
α1β1 L   C                               E A (59), (136) 
α2β1 L   C                                MMP1 E (133), (27), 
α3β1 L         F  E A (59), (27), 
(136),(38) 
α4β1            F    O    V   E (133), (20) 
α5β1 L         F  E A (59), (27), 
(135), (136) 
α6β1 L  E A (59), (27), 
(136) 
α7β1 L   (133),(127) 
α8β1           F                 T              TGFβ  (133), (134) 
α9β1 L                O        T  E (133), (137) 
α10β1     C   (133) 
α11β1     C   (133) 
 
Table 1.  Integrin-ECM Interactions 
This expression table details a literature review of known ligands for given 
integrins as well as cell types they have been shown to be expressed on.   
L = Laminin 
C = Collagen 
F = Fibronectin 
O = Osteopontin 
V = Vitronectin 
T = Tenascin 
W = von Willebrand factor 
A = Astrocytes 
E = Endothelial Cells. 
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A Role for αvβ8 Emerges in Gliomagenesis 
 As previously discussed, knocking out αvβ8 in the mouse brain results in 
significant hemorrhaging.  Upon closer inspection it can be seen that there is 
endothelial cell hyperplasia as well as distorted and abnormal formation of the 
vasculature.  In comparison, these phenotypes look very similar to the vasculature 
that is seen in GBMs.  Tchaicha and colleagues were the first to draw a link 
between αvβ8 and the angiogenesis of astrocytomas.  Transformed mouse 
astrocytes were cultured from both WT and β8 knockout mice and injected back into 
the mouse brain.  Upon sacrificing the animal it was noted that β8-/- tumors 
displayed large amounts of hemorrhaging (Figure I1 A).  These tumors were 
inspected more closely by performing immunohistochemistry for H&E as well as the 
blood vessel marker CD34 (Figure I1 B).  It can be seen that the WT tumors have 
normal vasculature formation.  However, when the integrin is knocked out the blood 
vessels become very distorted, which is a likely explanation for their hemorrhaging.  
Additionally, one can appreciate the hyperplasia with their being more endothelial 
cells per blood vessel and also more blood vessels in total.  This has led out lab to a 
new model for αvβ8 in GBMs (Figure I1 C).  Normal astrocytes and progenitors 
express the proper level of αvβ8.  This allows for a homeostasis to take place which 
regulates blood vessel development via TGFβ signaling.  At some point in a 
patient’s life their cells transform through a preexisting genetic mutation or one that 
was induced through environment.  As the pathology of the tumor progressed 
subpopulations of cells have varying levels of the integrin.  Those with low levels of 
β8 lead to tumors that are more permeable and angiogenic as was described by Dr. 
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Tachicha or the McCarty lab(62).  Preliminary results, along with published finding 
suggesting a role for αvβ8 in cell motility; therefore we predict high levels of β8 lead 
to increased invasiveness in GBMs.   More specifically, this has led us to our 
hypothesis that αvβ8 integrin-dependent activation of TGFβ signaling pathways as 
well as cytoplasmic tail signaling drive astrocytoma cell migration and invasion 
(Figure I1 D).  This data has been published(215).  
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Figure I1. 
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Figure I1. A Model for β8 Regulated GBM Invasiveness 
(A) WT transformed mouse astrocytes and β8-/- transformed mouse astrocytes 
were injected into the brain of nude mice.  Please note the large amount of 
hemorrhage that takes place when the integrin is knocked out.  (B) 
Immunohistochemistry the tumors stained for H&E and blood vessel marker 
CD34.  Please note the distorted vasculature present in the β8-/- tumors.  (C) A-
Normal astrocytes and progenitors express αvβ8 and regulate blood vessel 
development via TGFβ signaling; B-Genetic mutations induce transformation; 
C-As the pathology progresses subpopulations have varying β8 integrin 
levels and low β8 leads to more angiogenesis and vascular permeability; D-
High β8 leads to increased invasiveness.  (D) Model for the role of αvβ8 in 
glioma invasiveness whereby separate signaling pathways take place.  One 
originating from the cytoplasmic tail of β8 and the other from the extracellular 
portion of the αvβ8. 
 
D 
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Chapter 2: 
Materials and Methods 
 
Immunocytochemistry and Immunofluorescence 
 When cells are ready to be analyzed they are washed twice with PBS.  4% 
PFA is then added for 10 minutes, washed twice with PBS, .5% NP40 Buffer added 
for 10 minutes, washed twice with PBS, and left in 10% serum of choice for 
blocking.  All of this took place at room temperature.  Fixed cells can then left at 4°C 
for long term storage.  Primary antibody is added in the previously mentioned 10% 
serum of choice and left to incubate overnight at 4°C.  This is then washed with .1% 
Tween20 for 5 minutes, and washed twice with PBS for 5 minutes.  The secondary 
is added in the same serum and left at 4°C for 2 hours.  This is removed, washed 
once with .1% Tween20, and twice with PBS for 5 minutes each.  The edge of the 
coverslip is dabbed on a napkin to remove excess liquid and they are carefully set 
face down on a 10μl drop of soft-set DAPI stain.  A modification of this procedure 
also allows for two primary and two secondary antibodies to be mixed and added at 
the same time.  Additionally, this procedure is used for tissue sections in which the 
tissue is deparaffinized through sequential exposures to varying levels of Ethanol 
and Xylene, dried, and surrounded with a Pap-pen. 
 
Immunohistochemistry 
 Paraffin sections were first de-paraffinized by placing them in xylene for 4 
minutes, xylene for 3 minutes, 100% ethanol for 2 minutes, 100% ethanol for 2 
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minutes, 95% ethanol for 1 minute, 95% ethanol for 1 minute, and 80% ethanol for 1 
minute.  The slides were then placed face up and the tissue outlined with a pap-pen 
(Invitrogen).  PBS was added to the tissue for 5 minutes to rehydrate the tissue.  
This was removed and the tissue was blocked with 10% swine serum in PBS that 
was ran through a .45μM polyethersulfone filter (Whatman).  This blocking step was 
done for 30 minutes at room temperature in a light sealed humidifying chamber.  
This was removed and the primary antibody was added.  This was in the same 
filtered 10% swine serum and was added over night at 4°C.  This was then washed 
twice in PBS+0.1% Tween-20 and then once with PBS.  Washing steps were each 
5 minutes and at room temperature.  This was removed and the tissue was 
quenched with 0.3% hydrogen peroxide (H2O2) for 10 minutes.  Fresh hydrogen 
peroxide is crucial as it reacts with ambient moisture over time.  This is then carried 
through 3 washing steps of PBS, again at 5 minutes per wash and at room 
temperature.  The secondary was added in 10% swine serum for 2 hours at room 
temperature (typically a swine anti-X biotin).  This was washed off in 2 washes of 
PBS+0.1% Tween-20 and then once in PBS.  This was then incubated with an ABC 
complex (Vectastain) for 30 minute at room temperature.  This was then washed 3 
times for 5 minutes at room temperature with PBS.  The tissue was the developed 
with DAB (Vector Laboratories) for 10 minutes or until obvious color changes.  This 
was then washed with water two times, 5 minutes each.  The tissue was then 
immersed in Hematoxylin Gill’s Formula (Vector Laboratories) for 3 minutes.  This 
was then washed in water twice for 5 minutes each.  It was then dipped in acid 
solution (2% glacial acetic acid in water) 10 times, dipped in water 10 times, dipped 
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in bluing solution (.45% NH4OH in ethanol) 10 times, and dipped in water 10 times.  
This was then ran through a sequence of alcohols that were 3 minutes in 75% 
ethanol, 3 minutes in 95% ethanol, 3 minutes in 100% ethanol, 3 minutes in 100% 
ethanol, 5 minutes in xylene, 5 minutes in xylene, and 5 minutes in xylene.  These 
were then let dry briefly and Cytoseal-XYL (Richard-Allan Scientific) was added on 
top of the tissue.  This was carefully covered with cover glass (Fisher Scientific) so 
as to prevent and minimize bubble formation. 
 
Frozen Sections 
 As previously described, animals were cardiac perfused with 4% PFA (in 
PBS) and sectioned coronally in 2mm portions.  These were left in 4% PFA over 
night.  This was followed by placing them in 10% sucrose for 4 hours at 4°C and 
20% sucrose overnight.  These tissue sections were then placed in Cryomolds® 
(Tissue-Tek) with embedding medium (Tissue-Tek).   This was flash frozen on dry 
ice and then stored at -80°C.  These were then placed on positively charged slides 
by the MDACC Histology facility for H&E and other staining, as necessary. 
 
Paraffin Embedded Sections 
 Following the previously mentioned cardiac perfusion and tissue sectioning, 
paraffin embedded sections were generated.  Sections of coronally sliced tissue of 
2mm thickness were placed in tissue cassettes.  These were submitted to the 
MDACC Histology core where the samples were embedded in paraffin.  7μM 
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sections were subsequently placed on positively charged glass slides.  The middle 
slide was H&E stained by the core for reference.  
 
Western Blot 
 Cells are washed with PBS and lysed with either RIPA or NP-40 lysis buffer 
(dependent on specific experiment).  The cells were removed with a cell scraper 
(Fisher Scientific) and put into 1.5ml Eppendorf tubes.  These we set on ice for 10 
minutes and then spun down for 15 minutes at 4°C at maximum RPM.  The pellet 
was discarded and the supernatant kept.  The resulting lysate was frozen and or 
BCA protein quantification was carried out.  The lysate was made with lysis buffer 
up to the desired concentration.  This was mixed with a loading buffer (either 
reducing or nonreducing) and boiled for 5 minutes at 100°C.  The sample was then 
cooled on ice and spun down to remove droplets from the top of the tube.  This was 
loaded onto a polyacrylamide gel for separation.  Following this step the gel was 
transferred on a PVDF membrane.  This membrane was washed in TBST 3 times, 5 
minutes each.  This was then blocked in 3% nonfat milk.  The primary antibody was 
added in this milk and left to rock overnight at 4°C.  This was removed and washed 
3 times with TBST, 10 minutes each.  The secondary antibody was added in 3% 
nonfat milk at room temperature for 1hr.  This was washed 3 times with TBST, 10 
minutes each.  Following this the membrane was dried and chemiluminescent 
regents (GE Healthcare) were added for 1 minute.  This was developed in a 
darkroom with chemiluminescent film (Fisher Scientific) for varying lengths of time.   
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Immunoprecipitation 
 Lysates were made with RIPA Buffer containing protease and phosphatase 
inhibitors.  The cells were left on ice for 10 minutes and then spun down at 
maximum RPM at 4°C for 15 minutes.  The supernatants were taken and then a 
BCA based protein quantitation method was used.  These were pre-washed with 
the agarose conjugated secondary antibody of choice.  This was tumbled at 4°C for 
30 minutes.  The supernatant was then removed and the primary antibody was 
added.  This was tumbled overnight at 4°C.  The secondary antibody was then 
added and tumbled for 2 hours at 4°C.  This was spun down at 500RPM for 5min.  
The supernatant was removed, leaving just the agarose.  This was then 
resuspended in 300μl of lysis buffer to wash and spun down at 500RPM.  This was 
repeated two more time.  Finally it was spun down so that only agarose remained.  
15μl reducing buffer was added and the western blot process was carried out. 
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In Situ Mixture Reaction Immunoprecipitation 
Pure proteins were added to a 1.5ml Eppendorf up to a final volume of 500μl.  
These are tumbled over night at 4°C.   
Peptides Product Numbers Peptide Amounts 
Latent-TGFβ 299-LT 84ng 
LAP 246-LP 55ng 
αvβ8 4135-AV 190ng 
Cilengitide BML-AM100 10μM 
Control Peptide BML-AM101 10μM 
 
The primary directed against β8 (Santa Cruz) is added and tumbled for 4 hours at 
4°C.  The agarose conjugated secondary is then added for 2 hours and tumbled at 
4°C.  This was then ran through the polyacrylamide gel separation and transfer 
procedure common to the immunoprecipitation protocol.  This is then probed for 
LAP. 
 
Biotinylation of Cell Surface Proteins 
 Wash cells 3x with 37°C PBS (semi confluent tumor cells grown on 10cm 
tissue cultures dishes).  Add 6ml of Sulfo-NHS-Biotin (Thermo Scientific #21217) at 
66ug/ml (in PBS) per dish for 20 minutes at 37°C.  Wash 2x with PBS and 2x with 
TBS at room temperature.  Lyse cells with 800μl NP-40 lysis buffer with protease 
and phosphatase inhibitors and cell scraper.  Put on ice for 15 minutes and spin 
down for 15 minutes at maximum speed.   Perform BCA and aliquot equal amounts 
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of protein into two tubes each.  Pre-wash by adding 50μl washed anti-Rb-Agarose 
to each, bring volume to 600μl and tumble for 30 minutes at 4°C.  Pull down 
agarose by spinning at 500RPM with microcentrifuge and transfer supernatants to 
new tubes.  Add 2.5μg of β8-4627 and αV-cyto primaries per corresponding tubes 
and tumble overnight at 4°C.  Add 25μl anti-Rb-agarose and tumble 30 minutes at 
4°C.  Spin down at 500RPM, remove supernatant, add 200μl lysis buffer, gently 
mix, spin, remove supernatant, and repeat this wash cycle two more times.  
Remove final supernatant, add 15μl of nonreducing sample buffer, boil for 5 
minutes, run samples on 7.5% agarose gel.  Transfer onto Immobilon-P membrane.  
Wash 3x with TBST, block in 3% BSA (in TBST) for 30 minutes at room 
temperature , wash 3x with TBST.  Wash with streptavidin AB for 30 minutes at 
room temperature, wash 3x with TBST, then add chemiluminescence for 
development.  
 
GTPase Activation Assay 
 GTP-bound Cdc42 and Rac1 were fractionated using GST-tagged p21 
binding domain (PBD) of Pak1 as previously described.  Rhotekin-conjugated to 
Agarose (Cytoskeleton, Inc.) was used for fractionating GTP-bound RhoA.  Cells 
were harvested in Mg2+ lysis buffer containing 25 mM HEPES, pH 7.5, 150 mM 
NaCl, 1% Nonidet P-40, and 10 mM MgCl2, supplemented with 1 mM DTT, 1 mM 
Na3VO4, 10 mM NaF, 10 mM β-glycerol phosphate, and EDTA free protease 
inhibitors (Roche).  The lysates were incubated with PBD or Rhotekin beads for 20 
min at 4°C. Following precipitation, the pellets were washed 3x with in Mg2+ lysis 
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buffer and then analyzed by Western blotting to determine levels of active 
Rac1,Cdc42 or Rho. 
 
Isolation of Primary Mouse Astrocytes 
 P0-P2 neonates were taken from sacrificed WT, αvKO, and β8 KO litters.  
Incisions were made in ear canals down to the nose, and then upwards down the 
midline of the skull from anterior to posterior.  The cranium was carefully opened 
with forceps and microscissors (Roboz Surgical Instrument Co. Inc.) and the brain 
removed and placed in a dish of sterile PBS on ice.  The olfactory bulbs and 
hindbrain were removed as well as the thin meningeal layer surrounding the 
remaining cortex.  The cortex was then split into its two hemispheres and opened so 
that the hippocampus could be removed.  The remaining tissue is minced with 
sterile razors in a separate dish with new PBS.  This tissue is again verified to not 
have meningeal tissue as it may lead to unnecessary heterogeneity of the cell 
culture.  The PBS and tissue was placed into a sterile tissue culture grade 15ml 
conical and centrifuged at 1000RPM for five minutes.  The PBS was removed and 
replaced with 5ml of a collagenase (Worthington) and DNase I (Sigma) in DMEM 
(Sigma) solution at 150units/ml and 40μg/ml, respectively.  This was resuspended 
and pipetted up and down several times for mixture.  This was placed on a rocker 
for 30 minutes at 37°C.  The tubes were centrifuged and the media aspirated.  5ml 
of low glucose DMEM (Sigma) with 10% calf serum (Thermo Scientific) and 1% 
Pen-Strep (Sigma) was used to resuspend the pellet and titrate it 20 times.  This 
homogenized tissue was then ran through a 70μm nylon sieve.  An additional 15ml 
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of media was ran over the cell strainer to push remaining bits through into a 50ml 
sterile conical.  This cell homogenate was then placed into canted neck 75cm2 
tissue culture flasks that were coated with 10μg/ml murine laminin (Sigma).  These 
cells are grown at standard tissue culture condition in an incubator at 37°C 5%CO2.  
After a week or full confluence the cells are shaken over night at 37°C and 
250RPM.  This was to prevent contaminating microglia and fibroblasts, which 
sometimes loosely grow on the surface of monolayers of astrocytes.  Other than cell 
type contamination, microglia presence is unfavorable because they release toxic 
cytokines.  These are then placed back in standard culture incubating conditions for 
recovery. 
 
Culturing Human GBM and Assorted Cell Lines 
 GBM cell lines U87, LN18, SNB19, LN229, LN428, LNZ208, and U373 were 
acquired from ATCC.  With U251 being kindly provided by Professor Oliver Bögler 
in the Department of Neurosurgery at M. D. Anderson.  These cells were grown in 
10% fetal bovine serum (Thermo Scientific) and 5% Pen-Strep (Sigma) in 
DMEM/F12 50/50 (Cellgro) as recommended by ATCC.  These medias were also 
supplemented with construct specific antibiotics, as necessary.  Norma human 
astrocytes (NHA) were acquired from Lonza and grown in Lonza provided media 
and supplements.  Transformed human astrocytes (THA) were donated by Dr. 
Russell Pieper and were derived from NHAs as previously described.  293T cells 
were acquired from ATCC and grown in DMEM-High Glucose media (Sigma) 
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supplemented with 10% fetal bovine serum (Thermal Scientific) and 1% Pen-Strep 
(Sigma).  This same media was also used for Mink lung epithelial cells (MLEC).  
 
Note: The previous protocol includes specific numbers, antibodies, and reagents 
that can be exchanged depending on specific experiment requirements. 
Prepare Anti-Rabbit IgG-Agarose by taking 1300μl, spinning down at low RPM, and 
removing the supernatant.  Add 600μl NP-40 lysis buffer with protease inhibitor 
(complete mini EDTA free) and phosphatase inhibitor(PhosSTOP), mix, spin down, 
remove supernatant, and repeat two more times.  Then add 600μl lysis buffer.  This 
mixture should always be resuspended before use, resulting in an approximate 1:1 
ratio of agarose:buffer. 
 
Transformation and Plasmid Preparation 
 Thaw tubes of NEB-5α cells, Puc-19 DNA, and constructs on ice.  Transfer 
the 50μl of cells into a pre-chilled round bottom tube and add 1μl of DNA.  Flick to 
mix and incubate on ice for 30 minutes.  Heat shock in a water bath at 42°C for 30 
seconds and place back on ice for 5 minutes.  Add 950μl SOC medium to each tube 
and shake for 1 hour at 37°C.  Transfer these cells onto a plate with appropriate 
antibiotics, smear, and let grow at 37°C over night.  Remove one colony and place 
into 5ml of 1X LB with appropriate antibiotics.  Shake at 37°C for 8 hours.  Transfer 
this into 50ml of 1X LB with antibiotics and shake at 37°C overnight.  Spin down for 
a pellet of bacteria that can be lysed and used for a Qiagen Midi Prep. 
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Virus Synthesis 
 Retroviral and Lentiviral vector DNA was transfected into ecotropic Phoenix 
cells rendering the viral product capable of delivering genes into dividing murine 
cells.  The following day the media was replaced with fresh, vectorless and 
reagentless media.  This media was incubated on the cells for 2 days.   
Cells of interested were washed with PBS once.  The virus containing media was 
then incubated with polybrene at a final concentration of 6μg/ml for 10 minutes at 
37°C.  This was then added to the cells of interest and let incubate at 37°C until the 
cells became semi-confluent.  The cells were then selected for and/or analyzed for 
appropriate proteins expression levels. 
 
Transfections 
 In a 60mm tissue culture dish 1μg DNA, 8μl Enhancer reagent (Qiagen), and 
8μl EC Buffer (Qiagen) is added to a total volume of 150μl.  This is mixed by 
pipetting 10 times and incubated at room temperature for 5 minutes.  25μl Effectene 
reagent (Qiagen)is added, mixed by pipetting, and incubated at room temperature 
for 8 minutes.  During this incubation time the cells are washed once with PBS and 
2ml media added.  After incubation, the mixture is filled to a total of 1.5ml with 
media, mixed, and added to the cells.  Construct specific selection agents are then 
used for selection. 
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shRNA Development 
 cDNA sequences to three different regions of human origin αv and β8 
subunits were chosen and verified to have minimal homology.  These were 
submitted externally (Integrated DNA Technologies) for synthesis of DNA 
oligonucleotides.  Each oligonucleotides was annealed into the pLB system with 
Xhol and Hpal restriction sites.  DH5α competent E. coli were transformed with the 
lentiviral vectors and grown on amp resistant LB plates.  Colonies were isolated and 
a Midi prep (Qiagen) was performed and the DNA was purified.  The sequence was 
verified (Lone Star Labs).  This was then transfected into 293-FT cells as previously 
described to generate lentivirus.  This was subsequently added to LN229, SNB19, 
and THA cells.  Knock down was examined by western blot, the best shRNAs were 
determined, and the cells were FACS sorted for further knockdown power.  The final 
selection was αvshRNA-#4 and β8shRNA-#6. 
 
siRNA Mediated Knockdown 
 Cells are plated at less than 50% confluency on 60mm tissue culture dishes.  
30μl of 20 μM siRNA is added to 30μl of antibiotic and serum free media.  Mix by 
pipetting.  In parallel, 3μl Dharmafect Reagent #2 is added to 147μl of antibiotic and 
serum free media and mixed by pipetting.  These two reactions are incubated for 5 
minutes at room temperature and then combined and incubated for 20 minutes at 
room temperature.  Cells are washed with PBS, and 4ml of serum containing media 
is added.  The contents of the reaction tube are added and the cell incubated at 
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37°C for 24 hours.  The media is then replaced with fresh media and a lysate is 
made 2 days later.  This amounts to 3 days after the initial addition of siRNA. 
 
Fluorescence-Activated Cell Sorting 
 FACS was carried out at the M. D. Anderson FACS facility on BD FACSAria 
II flow-cytometry cell sorters and assisted by Laboratory Manager  with over 20 
years of FACS experience.  Cells trypsinized, placed in PBS and sorted into chilled 
serum containing media.  Cells were gated to cell size, and fluorescence intensity 
as specified per experiment.  
 
Dish Coating Substrates 
 Substrates were used in tissue culture at the following concentrations. 
Fibronectin Sigma F2006 
A 24-well dish has 1.9cm2 of surface area.  It is recommended to be used at 2-
5μg/cm2, so I used it at 2μg/cm2.  This came out to 38μl of stock fibronectin plus 
462μl PBS per well.  Stock was made to 100μg/ml. 
 
Laminin L2020 
This was used consistently at a 1:300 dilution in PBS.  This comes out to 
101ng/cm2. 
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Vitronectin V8379 
This was recommended to be used at .1μg/cm2 which equates to 38μl stock into 
462μl PBS per well.  The stock concentration was 5μg/ml 
 
PDL P6407 70,000-150,000 mol wt (though the [30,000-70,000 mol wt P7280 is 
also possible for use)  With a larger weight the P6407 has a higher binding site 
density. 
This was made into a stock at 25μg/ml.  When using 500μl in a 24 well plate this 
works out to 0.526μg/cm2.  
 
Adhesion Assay 
 A 24-well plate was coated as dictated in the chart below for 2 hours at 37°C.  
The wells were washed three times with PBS and blocked with 300μl of 3% BSA for 
30 minutes.  The wells were then washed three times with PBS and the cells were 
left to adhere for 48 hours. 
Table 2. 
 Added per 
Well 
PBS per Well [Stock] μg/cm2 
Laminin 1.667μl 498.33μl 1mg/ml .0033 
Vitronectin 38μl 462μl 5μg/ml .1 
Fibronectin 38μl 462μl 100μg/ml 2 
LAP 300μl 200μl 5μg/ml .7895 
PDL 500μl 0μl 25μg/ml .526 
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PBS - 500μl - - 
 
Table 2. Substrate Dilutions  
Dilutions for various experiments that required the above substrates 
 
Proliferation Assay 
 For this assay, 25,000 cells were trypsinized, counted, and evenly distributed 
into wells of a 24-well plate.  Each time point consisted of 6 wells per time point.  
Each well was trypsinized and counted by hand under a microscope with a 
hemocytometer.  Time points were taken at 24 hour intervals.   
 
Scratch Assay 
 Cover glass with a 12mm diameter (Fisher) was placed in wells of 24-well 
plates.  Cover slips were coated with Laminin (Sigma) at 1:300 in PBS for 2hrs at 
37°C.  They were then washed with PBS and cells added in normal growing 
medium.  The cells were allowed to grow until confluent and were scratched linearly 
with a p10 pipette tip.  These were washed 1x with PBS to remove free-floating and 
weakly attached cells at the scratch margin and replaced with growth media.  The 
cells were fixed by washing once with PBS, adding 4%PFA for 10 minutes, washing 
once with PBS, adding .05%NP40 Buffer, washed once with PBS, and kept in 10% 
goat, donkey, horse, or swine serum. 
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Invasion Assay 
 BD BioCoatTM MatrigelTM Invasion Chambers were used with 6.4mm 
chamber size, .3cm2 membrane surface area and of 8μM pore size.  Inserts were 
rehydrated with 1% serum containing media (cell-line specific) and place at 37°C for 
two hours prior to the start of the assay.  Cells were trypsinized and resuspended in 
1% serum containing media (cell-line specific).  Cells were counted by 
hemocytometer and added at 50,000 cells per well into the top chamber with a total 
volume of the top chamber being .500ml.  .750ml of 10% serum containing media 
(cell-line specific) was added to the bottom chamber as the chemoattractant.    This 
was placed back at 37°C for 24 hours and invasion allowed to occur.  The following 
day the chambers were removed and the inside of the upper chamber was swabbed 
with cotton swabs to remove adherent but non invasive cells.  The upper chamber 
was then washed once with PBS.  The insert were then fixed in 2.5% grade II 
glutaraldehyde (Sigma) for 15 minutes.  This was removed and then incubated with 
0.5% Triton X-100 (Fisher) to permeabilize the cells for 3 minutes.  They are then 
submerged in filtered Gill’s formula hematoxylin (Vector Laboratories) for 30 
minutes.  This is then washed with ddH2O.  Membranes were out with a scalpel and 
placed cell-containing-side down on a drop of water on a glass slide.  The entire 
membrane was imaged at magnification (cell size dependent) to take overlapping 
pictures.  Images were then printed, and a macro sized membrane was constructed.  
All the cells were counted.  “Invasion Index” was calculated as giving a percentage 
of invasion relative to the control cell line.  The number of cells for the control cell 
line was used as the denominator for both that cell type and for the experiment cell 
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types.  This appears as Control Invasion Index = (Control #)/(Control #) ; 
Experimental Invasion Index = (Experimental #)/(Control#).  In this way the Control 
is always 1 (or 100%) while the experimental cell type can easily be viewed as a 
percentage relative to the control.   
 
 
Live Cell Imaging, Quantitation, and Track 
 Imaging was carried out with an Olympus IX81 inverted microscope.  This 
was manufacturer modified with a Retiga camera capable of capturing bight and 
fluorescent wavelengths (QImaging).  Addition modifications included a motorized 
stage (ASIimaging), manual analog-stick apparatus (Applied Scientific 
Instrumentation) and a built-to-order live cell environmental chamber 
(PrecisionControl) with a temperature and CO2 controller (PrecisionControl).  This 
was attached to an external CO2 tank (Matheson Tri-Gas) and regulator (Fisher 
Scientific).  The software used was SlideBook 4.2 (Intelligent Imaging Innovations).  
Prior to start of the assay the microscope is warmed to 37°C with 5% CO2 and the 
humidifier is activated over night.  Cells were plated to confluence on coated 24-well 
glass tissue plates (Greiner Bio-One) and scratched with a p10 pipette tip vertically.  
This was washed with PBS to remove floating cells and fresh media was added.  
Images were taken at 100x every 30 minutes over a 48 hour period.  Movies were 
then compiled from these snap shots in SlideBook.  Fluorescent images were taken 
with exposure of one wavelength at a time and overlaid with the software during the 
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compiling process.  This was to generate the clearest images as well as to prevent 
fluorophore cross excitations. 
 
Luciferase Assay 
 Previously described mink lung epithelial cells (MLEC) were transfected with 
a stable PAI1-Luciferase construct.  These cells were plated on poly-lysine (Sigma) 
coated dishes.  The tumor cells (cells of interest) were grown until 80% confluent.  
These are washed with PBS to remove serum and add serum-free media over 
night.  The MLECs were also washed with PBS and replaced with serum-free 
media.  The following day the media from the tumor cells is added to the MLECs for 
4 hours.  Control medias were also used with exogenous TGFβ.  These cells were 
washed with PBS and lysed with proprietary buffers (BD Biosciences).  Luciferase 
reporter reagent and instructions were used for subsequent steps.   
 
 
Stereotactic Injection of Modified and Non-Modified GBM Cell Lines 
“Nude” male NCR nu/nu mice (Jackson Laboratories) were used for all in-vivo 
tumor model work.  These mice were anesthetized with Avertin at the 
recommended 0.25mg/g.  After intraperitoneal injection the mice were continuously 
checked for paw sensitivity and other symptoms of general anesthetic induced 
unconsciousness.  The mouse was then placed in a stereotactical surgical frame 
with a fixed needle to stabilize the mouse and to allow for geographically consistent 
injections (Image 1A and 1B).  The surgical area was sterilized and with a sterile 
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surgical scalpel (BD Biosciences) an anterior to posterior incision was made to 
expose the cranium (Image 1B).  Once open, coordinates 1.5mm rostral and 1.5mm 
anterior of the bregma were set and recorded on the skull.  This spot was drilled 
with a small bit dental drill.  Once open the needle was placed 3mm below the pail 
surface and a 3μl solution of cells was injected containing 100,000 cells over a 3 
minutes period using an automated micropump (Stoelting Instruments).  The hole 
was filled with bone wax and the skull was closed with surgical stables.  In these 
experiments the cells were sorted for GFP, counted, and directly injected for the 
best knockdown.  Animals were kept in MDACC animal facility and watched daily for 
neurological phenotypes, physical weight loss, and other abnormalities. 
 Tumor-bearing and control mice were sacrificed within 24 hours of each 
other.  These mice were anesthetized with .5-1mg/g of Avertin.    Their chests were 
entered through the diaphragm and opened.  A needle was inserted in the lower left 
ventricle of the heart.  This needle was attached through surgical tubing to an open 
syringe containing 4% PFA.  As the heart began to swell the right auricle was 
snipped.  This allowed an exit point for blood and PFA as the mouse was cardiac 
perfused.  The brains were then carefully removed and set into a brain shaped 
cassette where they were coronally sliced in 2mm sections, accounting to tissue 
shrinkage that occurs with PFA exposure.  The tissue was then submitted to 
MDACC Histology Core for serial 7μM sections that were placed on glass slides for 
later staining and examination.   
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VEGF ELISA 
 For this assay 500, 000 cells placed in 6-well plates.  The serum containing 
media was washed with PBS to remove residual VEGF and replaced with serum-
free media over night.  This media was harvested and filtered through a .45μM filter 
to remove cell debris.  This, along with control medias (serum containing, serum 
free, and serum free with VEGF) were used with the VEGF kit (R&D Systems).   
 
Statistical Analysis 
 Invasion assays were normalized to the control by dividing the experiment 
and control samples by the average of the controls.  This gave the control a value of 
1 and the experimental a value relative, in percentage, to the control for best 
perspective.  Statistical significance was determined by the student’s t-test. 
 
Antibody Usage Guidelines 
Table 3. 
Name Company 
Product 
Number 
Dilution  Mol Wt Applications  
Nestin Neuromics 
CH23001 
1:100 - IF Chicken 
Smad3 Epitomics 
1880-1 
 60 WB  
Actin  1:5000 37 WB  
PKCzeta Cell 
Signaling 
9372 
 78 WB  
Desmin 40245  53 WB  
GFAP pAb  1:200 - IF Rabbit 
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GFAP mAb  1:250 - IF Mouse 
S100 Abcam 1:100 - IF Mouse 
NeuroFilamen  1:250 - IF Mouse 
pERK Cell 
Signaling 
9106s 
1:1000 42, 44 WB  
pAKT Cell 
Signaling 
9271s 
1:1000 60 WB Rabbit 
Total AKT Cell 
Signaling 
9272 
1:1000 60 WB  
αv-cyto Custom 1:3000 150 
NonRed 
WB/IP Rabbit 
Β8-4627 Custom 1:3000 100 WB/IP Rabbit 
IgG Santa Cruz-
2027 
 - IF/IP Rabbit 
GDI-1   28 WB/IP  
GDI-2   28 WB  
Rac1 Millipore 1:500 21 WB  
GFP AB290 1:3000 25 WB/IP  
GFP  1:3000 25 WB/IP  
Myc Santa Cruz 
789 
 as 
tagged 
WB  
αv BD 
Biosciences 
 125 WB/IP Mouse 
pSrc Cell 
Signaling 
2101s 
1:1000 60 WB Rabbit 
pSmad2 Cell 
Signaling 
3101s 
1:1000 60 WB Rabbit 
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pSmad2 Cell 
Signaling 
3104s 
1:1000  WB Rabbit 
pSmad1 Cell 
Signaling 
9511s 
1:1000 60 WB Rabbit 
Hif1α  1:1000 125 WB  
FAK Cell 
Signaling 
3284s 
1:1000   Rabbit 
P2Y2  1:600   Rabbit 
p-β Catenin Cell 
Signaling 
9561s 
1:1000   Rabbit 
pFAK FM1211 1:1000  WB Mouse 
Β1 Millipore 
MAB1997 
1:1000  WB/IP Rat 
Β3 AB1932 1:1000  WB/IP Rabbit 
Β5 Ab1926 1:1000  WB/IP Rabbit 
Β6 Santa Cruz 
15329 
1:1000  WB/IP Rabbit 
Smad 2/3 3102 1:200   Rabbit 
PTEN MAB4037 1:50   Mouse 
N-Cadherin SC-1502 1:200   Goat 
 
Table 3. Antibody Information 
A catalog of various antibodies used throughout this work. 
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Chapter 3: 
αvβ8 Extracelluar Signaling: Determining Functional Roles for αvβ8 Integrin 
in Glioma TGFβ-Induced Invasiveness. 
 
Introduction 
 Glioblastoma multiforme (GBM) is the most common type of primary 
malignant brain tumor.  While their overall rate of occurrence is low, at around 
25,000 new cases per year in the United States, they cause a very high mortality 
rate(138).  One of the distinguishing hallmarks of GBMs is their invasiveness.  While 
a primary mass can be surgically resected, individual tumor cells that have invaded 
into the surrounding healthy tissue cannot be which can lead to satellite tumors.  
This makes the invasive phenotype an important property to understand. 
 Previously, our laboratory has shown that αvβ8 plays a key role in 
development of the vascular network of the mouse brain.  More recently this work 
has been extended to show a role in GBM angiogenesis.  The pathway investigated 
in the process of deciphering angiogenic phenotypes was an extracellular signaling 
pathway that involved the activation of LAP-TGFβs by αvβ8.  Here we begin to 
explore how this extracellular activation of TGFβ plays a role in GBM invasiveness, 
and investigate it in the context of autocrine and paracrine GBM cell - GBM cell 
signaling.  Previously differences in cell polarity, morphology, and invasiveness 
were seen with manipulation of β8 levels but these phenotypes were left largely 
unexplored.   
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 Here we hypothesize that abnormal αvβ8 expression contributes to the 
characteristic invasive phenotype of GBMs through TGFβ signaling.  Herein, 
molecular biology and cell culture techniques were used to manipulate β8 
expression and distinguish potential new roles for αvβ8 in in-vitro invasive 
phenotypes.     
 
Primary Astrocyte Isolation 
 Though previously conducted, this exercise was repeated for verifying 
previous results and accountability for those thereafter.  P0-P2 pups were taken 
from wild type (+/+), αv knockout (αv-/-), and β8 knockout (β8-/-) litters.  Pups were 
segregated based on obvious intracerebral hemorrhaging and placed into likely 
categories of knockout and wild-type (WT).  Genomic tail DNA was then used for 
PCR to verify individual mice as their astrocytes were being cultured in-vitro.  The 
cells were placed on dishes coated with the basement membrane Laminin, which is 
known to support primary astrocyte growth (139).  Additionally, the McCarty lab 
generated β8 antibody was used to verify knockout of this integrin in β8-/- astrocytes 
for future use (Figure 1). 
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Figure 1. 
 
Figure 1. 1° Astrocyte Western 
β8 knockout and Wild-Type mouse astrocytes were blotted with an generated 
antibody against the cytoplasmic portion of β8 and with Actin.  
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 Wild-type, αv knockout, and β8 knockout primary astrocytes were then 
transduced to forcibly express E6 and E7 proteins of the human papilloma virus 
(HPV).  The E6 oncogene inhibits the p53 tumor suppressor by stimulating its 
ubiquination and proteosome degradation while the E7 inhibits Rb by preventing its 
interaction with transcription factor E2F.  This leads to a perpetually activated cell 
cycle.  This process generated immortalized cell lines that are biologically relevant 
since p53 and Rb loss of function has been seen in human glioblastoma multiforme.  
Using the same delivery system, human oncogenic Ras (HRasV12) was also 
transduced into the cells. 
The transformed human astrocytes (THAs) underwent a similar process 
except utilizing amphotropic Phoenix cells that are capable of delivering genes into 
human cells.  Additionally human telomerase reverse transcriptase (hTERT) was 
used to prevent telomere shortening to lead to immortalization. 
  Additionally, it is critical to identify integrin expression at the cell surface as 
that is required for extracellular TGFβ activation and TGFβ mediated pathways.  
This was accomplished with the use of amine-reactive biotin to label all of the 
extracellular amine sites of the proteins.  Since no expression of αv or β8 was seen 
in the knockout cells, biotinylation was carried out on WT cells.  All of the cell 
surface proteins were biotinylated and those associated with αv were pulled down 
and blotted with reagents reactive to biotin(Figure 2).   This revealed the presence 
of both αv and β8 proteins in the primary, immortalized, and transformed cells 
(Figure 2).  Additionally, it revealed that as the transformation process takes place 
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there is less extracellular αv and β8 expression.  This was also seen in the 
expression levels of these proteins by western blot (Figure 2). 
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Figure 2. 
 
 
 
 
Figure 2.  Mouse Astrocytes Lose Integrin with Transformation 
(A) Primary (1°), immortalized (I), and transformed (mTA) mouse astrocytes 
were biotinylated.  An anti-αv antibody was used to pull down all associated 
proteins and blotted with a biotin reactive agent.  This revealed two bands 
being associated with αv and β8.  Note the lack of αv and β8 expressed on the 
surface of primary and transformed αvKO cells. (B) Primary (1°), immortalized 
(E6/E7), and transformed (E6/E7 + hRAS) mouse astrocytes were analyzed by 
western blot.  Wild-type cells show that as they are immortalized and then 
transformed expression levels of β8 and αv decrease.  β8 knockout and αv 
knockout cells lines were also used as controls to verify antibody specificity. 
A 
B 
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 Additionally, the transformed cells were checked for surface expression of 
various integrins where it was seen that α5, α6, and β1 surface expression was 
present in all cells and that this expression did not change with immortalization 
(Figure 3).  Additionally, this experiment verified that β8 does not pair with these 
alpha subunits as they would also have been biotinylated.  This also revealed that 
β1 does not pair with α6 or α5 in transformed mouse astrocytes as was previously 
thought. 
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Figure 3. 
αvKO αvWT β8KO   αvKO αvWT β8KO    αvKO αvWT β8KO
α6                 α5                  β1
 
Figure 3. α6, α5, and β1 Biotinylation 
Transformed mouse astrocytes were biotinylated and pulled down with α6, 
α5, and β1 antibodies, revealing proteins paired with them.  β8 did not pair 
with these proteins.  Note, during pull down of β1 the lower band is β1 and the 
upper band is an α subunit.    
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Human GBM Cell-Line Characterization 
 Human GBM cell-lines were then characterized for expression of αv and β8 
integrins.  Figure 4 demonstrates the expression levels of the integrin in various 
cells lines.  Here it is seen that while αv remains relatively unchanged in human 
GBMs the level of β8 varies.  It is also interesting that transformation of human 
astrocytes decreases the expression of both integrins, just as was seen in 
transformed mouse astrocytes.  Due to their low expression of β8, U87 was 
selected for further studies.  As we believe high levels of β8 integrin positively 
influence the invasiveness in GBMs, SNB19 and LN229 cells were chosen for their 
robust levels of the integrin as well as their ubiquity in the literature. 
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Figure 4. 
 
Figure 4. GBM Cell Lines Express Varying Levels of Integrin β8 
Detergent-soluble lysates were made from seven different GBMs of human 
origin as well as transformed human astrocytes (THA) and the normal human 
astrocytes (NHA) they were derived from.  Note that GBM cell lines express 
varying levels of integrin β8 and near constant levels of integrin αv.   
 
 
 
 
 
 
 
 
 
 
 
 52 
 
 Following this it was critical to determine if that these integrins were also 
expressed on the cell surface.  Membrane-impermeable amine-reactive biotin was 
added and proteins αv and β8 were pulled down.  It was seen that not only were the 
integrins expressed on the cell surface, but that this expression also correlated with 
the levels seen in whole cell lysates (Figure 4-2).  i.e. High expression of total and 
surface β8 in LN229 and low expression of total and surface β8 in U87 cells were 
correlated. 
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Figure 4-2. 
 
 
Figure 4-2. Integrin Subunits αv and β8 Pair in GBM Cell Lines 
Membrane-impermeable amine-reactive biotin was used to label extracellular 
proteins.  Antibodies targeting the cytoplasmic domains of αv and β8 
integrins were used to immunoprecipitate the respective complexes.  These 
were then reduced to disrupt subunit interactions and subsequently probed.  
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Overexpression of β8 in GBM U87 cells Correlates with VEGF Expression 
 A previous study by our lab has suggested that levels of the integrin β8 may 
be involved in angiogenesis.  Therefore we decided to further investigate this here; 
anticipating changes in VEGF levels with β8 integrin manipulation.  U87 cells were 
transfected with a pcDNA4.0 plasmid harboring the full-length human β8 cDNA 
which overexpressed β8 in U87 cells (Figure 5).  While it was seen that β8 was over 
expressed, αv was not.  Morphologically these cells also appeared longer in 
comparison to untransfected and mock transfected U87 cells.  Additionally, β8 
expression correlated with high amounts of VEGF secretion, as measure by hVEGF 
ELISA.  However, this correlation did not extend to the varying levels of β8 in LN229 
cells with high and knocked down β8 (Figure 5).  This may be due to a specific 
genetic difference between the two cell lines.  Interestingly, THAs with the integrin 
β8 knocked down using shRNA showed a decrease in VEGF when compared to the 
control non-targeting shRNA cells (NT-pLB), as determined by ELISA.  This fits with 
the previously mentioned results in U87 cells.   
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Figure 5. 
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Figure 5. U87 Cells Secrete VEGF with β8 Overexpression 
(A) Parental, mock transfected, and three clones of U87 cells overexpressing 
the integrin β8 were blotted for the protein.  While the integrin increased, the 
levels of αv did not change.  (B) Various cell lines, including U87 and U87+β8 
were checked for VEGF levels with an ELISA.  Please note the relatively low 
levels of VEGF in U87 cells with low β8 expression and high VEGF levels in 
U87 overexpressing β8.  (C) THA cells were transfected with control and 
β8shRNA.  Please note the decreased expression of the integrin did not 
change the levels of αv protein.  Decreased β8 integrin levels resulted in 
decreased VEGF secretion.  
 
 
 
 
 
 
 
 
 
 
 
C 
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Manipulation of β8 Integrin Levels in LN229 and SNB19 Human GBM Cells 
 LN229 human GBM cells were transfected with lentivirus to express an 
empty non targeting (NT) pLB construct and a pLB-β8shRNA construct that were 
previously described.  This system allowed for the co-expression of GFP and an 
shRNA.  Due to this, the cells with higher GFP expression often result in better 
knock down.   This also allowed for the use of FACS to select the desired level of 
knock down.  After addition of the shRNAs there was no obvious phenotypic 
difference between the cells.  It is interesting though that after passaging the pLB-
αvshRNA cells could not adhere to plastic tissue culture dishes or culture dishes 
coated with Laminin.  This resulted in total cell death.  By definition, loss of αv 
means the loss of αv containing integrins, so it is likely that one or a combination of 
these integrins are required for cell adhesion and or survival(19,134,140).  This 
situation was also the case for SNB19 cells with pLB-αvshRNA (data not shown).  
For this reason pLB-αvshRNA LN229 and SNB19 cells were not pursued for further 
in vitro work.  However, it remains to be seen whether αv integrin is required for in 
vivo cell survival. 
 LN229 NT and LN229 pLB-β8shRNA #6 cells were sorted for the top 10% of 
GFP positive cells.  This resulted in the additional knockdown that is seen in Figure 
6B.  Additionally the knockdown was seen to decline from cells passaged twice, to 
five time, to seven times (data not shown).  Because of this, cells used thereafter 
were of low passage.  Due to the cell death that occurred along with αv knockdown, 
it was imperative to check the growth patterns of the LN229 β8shRNA cells.  A 
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proliferation assay was conducted and it was seen that growth differences were not 
seen as cells grew to confluence in-vitro, which was up to 72 hours (Figure 6C). 
 Utilizing these same shRNAs, β8 integrin was also knocked down in SNB19 
and THA cells.  After sorting for the top 10% of GFP positive cells the knockdown 
was measured (Figure 7).  Additionally, it was seen that there are no differences in 
proliferation between the two shRNAs when placed into SNB-19 cells (Figure 7). 
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Figure 6. 
 
 
            
 
 
A 
C 
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Figure 6. shRNA Mediated Knockdown of β8 in LN229 Cells Does Not 
Influence In-Vitro Growth 
(A) Human GBM LN229 cells were transduced with two constructs directed 
against αv and two directed against β8.  Note the low levels of integrin 
expression for #6 and #4 relative to parental cells.  mWT are WT whole mouse 
cortex lysates.  (B) β8shRNAs #6 was then taken and sorted for the top 10% of 
GFP positive cells.  This resulted in the additional knockdown seen.  (C) This 
proliferation assay revealed there is no difference in in-vitro growth when the 
integrin is knocked down with shRNA. 
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Figure 7. 
 
 
 
 
 
Figure 7. shRNA Mediated Knockdown of β8 in SNB19 Cells Does Not 
Influence In-Vitro Growth 
(A) Parental control, non-targeting, and β8shRNA SNB19 cells were blotted for 
integrin expression.  Note the β8 knock down in the β8shRNA cells . (B) This 
proliferation assay revealed there is no difference in in-vitro growth when the 
integrin is knocked down with shRNA. 
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Integrin Subunit αv Plays a Major Role in Migration 
 WT and αvKO transformed mouse astrocytes were analyzed for migration 
related differences by plating them on laminin coated glass coverslips and 
scratching them once they were confluent.  This revealed a striking difference 
where the cells did not move in to fill the wound as they did with WT cells.  This is of 
interest because those with αv knocked out had no αv associated integrins.  Further 
experiments with live cell imaging revealed that the transformed αvKO cells were 
indeed moving, but just not into the wound (video not shown).  The cells would 
migrate towards the scratch wound, but not fill it as though a barrier was present.  
They would then move vertically along the margin of the wound.  The cells 
continued to move in this pattern over the 48 hours period analyzed (data not 
shown).  The cells were let go beyond confluence up until cell death; they still did 
not cross the barrier.  Though real time video capture cannot be displayed Figure 9 
best represents the pattern of cell movement just after a scratch is made.  Note the 
original scratch is not a smooth line (Figure 9).  However, after 24 hours the cells 
move towards the scratch barrier and halt forward progress and only move parallel 
to the margin. 
 Following this observation, a rescue experiment was attempted to see 
whether WT transformed mouse astrocytes could rescue the migration defect seen 
when αv integrins are knocked out.  For this the transformed mouse astrocytes 
were stably transfected with an RFP vector while the αv knockout cells were 
transfected with a stable red fluorescent protein (GFP) construct.  Both sets of cells 
were sorted for maximum fluorescence.  Cells were first imaged separately where 
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the phenotypes seen in non transfected cells persisted.  The two cell types were 
then mixed in a 50:50 ratio and scratched as done before.  It was seen that as time 
elapsed the αvKO cells were preventing the WT cells from filling the wound in the 
manner they do when only WT cells are present (Figure 10).  Following this 293T 
cells were transfected with RFP and also ran through this mixing experiment.  It was 
again seen that the αvKO cells inhibited the migration of another cell type.  
Interestingly, 293T cells do not express β8 (data not shown), while WT cells do.   
 WT cells contain β8 integrin which is able to activate TGFβ while αvKO cells 
do not.  The rationale behind this mixing experiment was that the WT cells would be 
able to activate the TGFβ which could then signal on the αvKO cells, rescuing the 
phenotype.  However, since this did not happen it suggests an additional pathway is 
present that is independent of TGFβ activation.  These experiments were also 
repeated in reverse with WT transformed mouse astrocytes expressing the RFP 
and the αvKO transformed astrocytes and 293T cells expressing GFP. 
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Figure 8. 
 
Figure 8. Loss of αv in Transformed Mouse Astrocytes Alters In-Vitro Cell 
Migration 
Wild-type and αv knockout transformed mouse astrocytes were grown to 
confluence on laminin coated glass cover slips.  They were scratched and 
fixed after 12 hours.  Immunofluorescence was conducted with a green 488nm 
secondary and  tubulin and phalloidin primary antibodies.  Tubulin stains for 
microtubules while phalloidin marks the actin.  Note the complete lack on 
migration into the wound in αvKO mouse transformed astrocytes.  
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Figure 9. 
 
 
Figure 9. Loss of αv in Transformed Mouse Astrocytes Does Not Inhibit Cell 
Movement 
Two scratch wounds were fixed at two time intervals after the scratch of αvKO 
cells.  The 0hr (left) scratch has a jagged and uneven edge as cells were torn 
away from the wound with the scratching motion.  After 24 hours (right) it is 
seen that the cells will migrate to the wound edge, but not farther. 
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Figure 10. 
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Figure 10. WT mTAs Cannot Rescue the αv-/- mTA Phenotype 
(A) Using a live imaging microscope cells were imaged over 36 hours.  The 
images depicted are from the same well and are screen captures of a movie 
generated.  In the top three panels transformed wild-type mouse astrocytes 
stably expressing RFP were plated, scratched and imaged.  The second set is 
transformed αvKO mouse astrocytes.  The bottom row of panels is a 50:50 
mixture of the two cell types.  Note the migration of WT cells and lack of 
migration for the αvKO cells and also how the αvKO cells inhibit the migration 
of WT cells when the two are mixed. (B) 293T cells were also transfected to 
stably express RFP.  Note how in the mixture experiment the GFP positive 
αvKO cells inhibit the migration of the RFP positive 293T cells. 
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Integrin Subunit β8 Plays a Major Role in Migration 
 Transformed human astrocytes (THA) with the previously described non-
targeting shRNA and β8-targeting shRNA were used for a migration assay.  These 
cells were plated onto laminin coated glass wells of a 24-well plate, scratched, and 
imaged over 36 hours.  Wells with and without exogenous TGFβ were analyzed.  By 
following the time lapse file frame by frame it was seen that knocking down β8 
reduces the time it takes for the scratch region to fill (Figure 11).  Additionally, it was 
seen that the addition of exogenous TGFβ can partially rescue this defect.  This 
was further quantified and there was a statistically significant decrease in the 
amount of time it took the NT and β8shRNA cells to fill the wound (p-value = .006).  
There was also a significant difference (p-value = .03) for β8shRNA THAs with and 
without the exogenous TGFβ (Figure 11).  As TGFβ rescued this phenotype it 
suggests that the pathway involved with this molecule is the origin on the 
phenotype. 
 In analyzing this phenotype polarity proteins were also examined.  Confluent 
THAs expressing the NT-shRNA or the β8shRNA were scratched and fixed after the 
initial stages of cell polarity.  These were stained with paxillin, a marker of focal 
contacts and the actin marker, phalloidin.  It may been that the control THAs 
polarize into the wound region as expected while those with less β8 illustrate 
abnormal cell-ECM contacts (Figure 12).  The focal contacts are at the leading edge 
of the cell in the control panel but are dispersed when β8 is knocked down.  
Additionally, the actin cytoskeleton is stretched in the direction of cellular 
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movement, into the wound, for the control.  While with β8shRNA the actin pattern is 
hashed with no consistent direction (Figure 12). 
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Figure 11. 
 
 
Figure 11. β8 Dependent Migration Defects Are Partially Rescued by 
Exogenous Active-TGFβ 
(A) Transformed human astrocytes (THAs) control (Non-targeting shRNA) and 
β8shRNA cells were time-lapse imaged.  It can be seen that THA-β8shRNA 
cells migrate to fill the wound slower than those with the THA-NTshRNA.  
Note the partial rescue of this phenotype with exogenous 1ng/ml TGFβ is 
added.  (B) Quantitation of scratch assay.  *P-value = .006   **P-value = .03  
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Figure 12. 
 
 
Figure 12. β8 Knockdown Induces Polarity Dependent Phenotypes 
A scratch assay was performed on a confluent monolayer of THAs with 
control NT-shRNA (A) and β8shRNA (B).  The initial states of polarity can be 
seen with anti-paxillin and anti-phalloidin.  Note how control cells polarize 
into the wound region while when β8 integrin is knocked down obvious 
defects are present.  These images are shown at 400x magnification. 
 
 
 
 
 
 
 72 
 
Integrin Subunit β8 Plays a Major Role in Invasion 
 Following the previously demonstrated phenotype of primary and 
transformed mouse astrocytes lacking their full migratory potential, invasion assays 
were performed to gain further perspective.  Primary mouse astrocytes were 
cultured from WT, β8-/-, and αv-/- mice.  These cells were run through an in-vitro 
invasion assay.  The same number of cells was added into 1% serum containing 
media.  Aliquots were made that contained cells at a concentration of 50,000 cells 
per 500 microliters media for each cell type and loaded into the chamber.  The 
chemo-attractant was set at 10% serum containing media in the lower chamber.  It 
was seen that half as many β8-/- primary astrocytes invaded compared to WT 
astrocytes.  αv-/- cells invaded minimally with just a few cells making it to the bottom 
of the membrane (Figure 13A).  Following this transformed mouse astrocytes were 
analyzed by the same method to determine their invasive potential.  It was seen that 
these cells followed a similar pattern where loss of β8 reduced in-vitro invasiveness 
by about 50% and loss of αv resulted in severe and near complete loss of invasion 
(Figure 13B).  Following these results an experiment was performed to determine if 
this phenotype could be rescued.  β8 was overexpressed in β8-/- cells as 
determined by western blot (Figure 5).  These were run through an invasion assay 
where it was determined that forcibly expressing β8 can increase the invasive 
potential by about 60% over the β8-/- cells (Figure 13C). 
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Figure 13. 
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Figure 13. Loss of β8 Reduces Invasion and can be Rescued in a β8 
Dependent Manner in Transformed Mouse Astrocytes 
(A) Invasion assays were performed on primary mouse astrocytes, (B) 
transformed mouse astrocytes, and (C) β8-/- transformed mouse astrocytes 
forcibly expressing β8.  Note how the loss of β8 reduces in-vitro invasiveness 
while re-expressing this integrin in knockout cells causes a statistically and 
biologically significant increase in invasiveness.  **p-value <.005 ; All other p-
values < .05 
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 Human glioblastoma cell lines were analyzed to determine how β8 may play 
a role.  A pool of siRNA directed against β8 and a pool of scrambled siRNAs were 
used on the SNB-19 glioblastoma cell line.  This expression was check by western 
blot (Figure 14A).  These cells were then ran through an in-vitro invasion assay 
where it was seen that knocking down β8 in the SNB19 human GBM cell line results 
in about 50% loss in invasiveness when compared to cells treated with scrambled 
siRNA (Figure 14B).  Additionally, this was attempted in LN229 human GBM cells.  
The knockdown of β8 was verified by western blot (Figure 14C).  These cells were 
run through an invasion assay using the same protocol as with the SNB19.  
Knocking down expression of β8 in human GBM LN229 cells resulted in 
approximately 50% reduced invasiveness suggesting role for this protein in GBM 
cells’ invasive phenotype (Figure 14D).   
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Figure 14. 
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Figure 14. Silencing of β8 Reduces Invasion in SNB19 and LN229 GBM Cells 
Untransfected, αv-siRNA, β8-siRNA, and scrambled-siRNA were added to 
GBM cell line SNB-19.  Normal mouse astrocytes (Brain) were used for 
antibody reference.  (A)Note the reduced expression of β8 when β8siRNA is 
added.  (B) When β8 is knocked down in SNB-19 human GBM cells, in-vitro 
invasiveness decreases by about 50%.  (C) Knockdown of β8 was verified by 
western blot in LN229 cells.  (D) In-vitro migration assay of LN229 human 
GBM cells with β8siRNA and scrambled siRNA.  Note how silencing of β8 
reduces invasiveness by about 50%.  p-value < .05 
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 Further verification was taken by checking the invasiveness with shRNAs.  
The previously used SNB19 cells with known shRNA knockdown levels were used 
(Figure 7).  It was seen that this caused a roughly 50% reduction in in-vitro 
invasiveness (Figure 15A).  Additionally a second GBM cells line, LN229 was 
checked.  The shRNA knockdown levels were previously identified (Figure 6B).  In 
these cells we also see a roughly 50% reduction of invasiveness when β8 is 
knocked down (Figure 15B).  In addition to these new shRNAs were used.  For 
clarification all previous experiments used a single shRNA sequence.  Here two 
new sequences were tested on LN229 cells (Figure 16A).  This knockdown worked 
well and it was next determined that these new β8 targeting shRNAs also lead to 
reduced invasiveness.  In LN229 cells this was seen to be a roughly 40% reduction 
in invasiveness.  As these shRNAs have weaker knockdown, all subsequent 
experiments used the original shRNA which has the best knockdown (Figure 6).  
Following this, previously described transformed human astrocytes (THA) were 
analyzed for their invasive potential.  The knockdown was verified by western blot 
and they were shown to reduce invasiveness by about 80% (Figure17).    
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Figure 15. 
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Figure 15. Knockdown of β8 Reduces Invasion in SNB19 and LN229 GBM 
Cells 
Previously described human GBM cells (A) SNB-19 and (B) LN229 were used 
for invasion assay.  Note how knocking down integrin β8 reduces 
invasiveness by ~55% and ~65%, respectively.  Knockdown efficiency 
previously demonstrated (Figure 7 and 6B). 
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Figure 16. 
 
 
 
Figure 16. Knockdown of β8 with Additional shRNA Sequences Reduces 
Invasion in LN229 GBM Cells 
(A) Two new shRNAs were placed into LN229 GBM cells.  (B) These same 
cells showed a decrease in invasiveness when ran through an invasion assay.   
 
A 
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Figure 17. 
 
 
 
 
Figure 17. Knockdown of β8 in Transformed Human Astrocytes Reduces 
Invasion 
(A) Transformed human astrocytes (THAs) have the integrin β8 knocked down 
with β8 targeting shRNA.  This blot was generated and previously published 
by Jeremy Tchaicha, Ph.D.(62) (B) Knocking down integrin β8 in THA cells 
reduced invasiveness by about 80%.   
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Integrin Subunit β8 Plays a Major Role in Invasion through TGFβ mediated 
signaling 
 
 Considering the results of Figure 11 and the previous invasion results I then 
decided to probe the canonical TGFβ pathway.  β8 integrin was previously 
examined for an extracellular presence (Figure 4-2) however it is possible that 
siRNA and shRNA may not knockdown the extracellular β8.  To address this 
biotinylations were performed.  Transformed mouse astrocytes were biotinylated to 
label all extracellular proteins and then immunoprecipitated with β8.  This reveals 
that β8 knockout cells do not have β8 (Figure 18A).  Next, SNB-19 cells that had 
β8shRNA were checked.  These showed that when the integrin was knocked down 
there was also less of it being displayed on the surface (Figure 18B).  LN229 cells 
were also checked.  After biotinylations they were immunoprecipitated with αv to 
pull down all αv bound proteins.  This revealed a significant band that correlated 
with integrin subunits β3, β5, and β8 and a reduction of this band when β8shRNA 
was present.  To be more specific the same procedure was performed on LN229 
cells pulling down β8.  There was a significant reduction in β8 being expressed on 
the cell surface.  Since no β subunits pair with β8, the band seen indicates residual 
β8 being expressed on the surface (Figure 18C).   
 A monoclonal antibody (MAB) directed against TGFβ was added to LN229 
cells that had been serum starved.  In doing so, TGFβ signaling could be stopped, 
preventing the phosphorylation of downstream Smads and TGFβ induced target 
genes that can lead to invasion(13,141,142).  We can see that serum starved cells 
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express very little pSMAD3 as would be expected (Figure 18D).  When active TGFβ 
was added to the cells that were in serum free media there was noticeable 
phosphorylation of SMAD3.  However, when active TGFβ was pre-incubated with 
the MAB pSMAD3 signaling was not as active as without the MAB.  This suggests 
that TGFβ can stimulate signaling downstream of the TGFβ1/2 receptor and that 
this activity can be attenuated by blocking the binding site of TGFβ.  Proper controls 
were checked by mixing active TGFβ with IgG.  Additionally, the inactive latent-
TGFβ was added, which did not activate downstream signaling.  Next an inhibitor of 
the TGFβ-receptor was analyzed for efficiency.  Serum starved LN229 cells showed 
little to no SMAD2 and SMAD3 phosphorylation (Figure 18E).  However after adding 
serum containing media both proteins became heavily phosphorylated indicating the 
ability of TGFβ to stimulate signaling downstream of the TGFβ receptor.  The 
inhibitor was pre-incubated on the cells allowing for time to bind.  When serum 
containing media was added the SMAD signaling decreased in a dose-dependent 
manner.  A proliferation assay was then performed on the cells to determine if 
changes in SMAD signaling could affect cell growth in-vitro.  There was no 
statistical or biological difference between the various conditions (Figure 18F).  
LN229 cells were then run through an invasion assay with the TGFβ MAB and the 
TGFβR1/2 inhibitor (Figure 18G).  By blocking TGFβ signaling the cells invade 50-
60% slower than those not treated; similar to the phenotype seen when β8 was 
knockdown or knocked out.  As β8 is known to activate TGFβ these results suggest 
their heavy involvement in TGFβ signaling.  Additionally, when β8 is knocked down 
TGFβ signaling also drops, as is indicated by a luciferase assay (Figure 18G). 
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Figure 18. 
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Figure 18. Surface Expressed αvβ8 Mediates TGFβ Signaling and TGFβ Mediated 
Smad Signaling Mediates Invasion 
(A) WT and β8-/- transformed mouse astrocytes were biotinylated and β8 was 
immunoprecipitated.  Note the high expression of cell surface αv and β8 in 
WT cells but the lack thereof in β8 knockout cells.  (B) SNB-19 GBM cells were 
biotinylated and β8 was immunoprecipitated.  Note the large amount of 
surface β8 in the control cells and the reduced expression in cells with 
β8shRNA.  (C) LN229 cells were biotinylated and immunoprecipitated with αv 
and β8 antibodies.  Note the decreased surface expression of β8 when it is 
knocked down with shRNA.  (D) Western blot of LN229 cells demonstrating 
the ability of exogenous active-TGFβ to stimulate SMAD2 phosphorylation 
and for an anti-TGFβ antibody to attenuate this response.  (E) Western blot of 
LN229 cells demonstrating the ability of a TGFβ receptor inhibitor to block 
downstream SMAD2 and SMAD3 phosphorylation.  (F) Proliferation assay of 
LN229 cells exposed to nothing, anti-TGFβ monoclonal blocking antibody, 
TGFβRI inhibitor (SBI), IgG, and DMSO (SBI is solubilized in DMSO).  (G) 
LN229 cells were run through an invasion assay after being pre-incubated 
with MAB and TGFβR inhibitor.  Note the decreased invasiveness in cells with 
blocked SMAD signaling.  (H) The TGFβ responsive PAI-1 promoter drove 
luciferase in this luciferase assay of THA cells.  Note roughly 80% decrease in 
luciferase activity in cells with β8 knocked down.  Figure 18H was generated 
by former graduate student Dr. Tchaicha.  (I) Smad4 is knocked down with 
shRNA in SNB19 GBM cells and transformed human astrocytes.  (J) SNB19 
cells with Smad4shRNA show reduced in vitro invasiveness. (K) THAs with 
Smad4shRNA show reduced in vitro invasiveness. (L) The previously 
discussed model of TGFβ activation shown with three points involved in 
TGFβ-mediated invasion, active-TGFβ, TGFβ Receptor, and Smad4 being 
targeted.  
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Discussion 
 Previously, our lab has seen that αvβ8 may play a role in primary mouse 
astrocyte migration.  This however was not explored in depth or in the context of 
glioblastoma multiforme.  The data generated and discussed in this chapter is the 
first to connect aberrant αvβ8 expression and function to invasive pathologies from 
normal astrocytes to transformed astrocytes to human GBMs. 
 Primary astrocytes were cultured from pups and the expression was verified.  
These were then immortalized with E6 and E7 to inhibit p53 and Rb as these 
proteins are known to experience loss of function in human GBMs.  They were split 
and some cell lots further transformed with HRasV12.  Since the mechanism being 
explored here involves the extracellular signaling, it is of importance to determine 
that αvβ8 is expressed on the surface.  This was verified by biotinylation.  It is 
interesting to note that as the primary mouse astrocytes become immortalized and 
then transformed they also begin to lose protein expression of both αv and β8 
(Figure 2).  As this loss is also seen on the cell surface it is likely to influence TGFβ 
signaling (Figure 1).  The reasoning behind this is not clear as later experiments 
revealed that the majority of GBM cell lines and primary GBMs have higher 
expression levels of the integrin, though the levels do vary (Figure4)(62).  One 
explanation may be that the primary and GBM cell lines analyzed are high grade 
GBMs while immediately after transformation the tumors cells are a lower grade.   
 Other integrin subunits were then analyzed whether they could potentially 
pair with β8.  α5 and α6 are alpha subunits known to bind to β1 in astrocytes but it 
is unclear whether it has been checked if these interact with β8 on the cell surface.  
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We determined these subunits do not interact with β8 as a band would have been 
seen in the 100kDa range; they however are very likely to pair with β1 as is 
expected (Figure 3).  This agrees with previous findings that β8 only pairs with αv.  
However, it conflicts with previous reports of α5 and α6 pairing with β1 (27,59,136). 
 Following characterization of transformed mouse astrocytes human GBM cell 
lines were analyzed.  Here it was seen that while αv protein levels remains relatively 
unchanged in human GBM cell lines the levels of β8 vary (Figure 4).  Additionally, it 
was again observed that a transformation of a primary cell line can cause loss of 
both αv and β8.  This was the case for human astrocytes (Figure 4).  Since THAs 
are more representative of human GBMs than transformed mouse astrocytes this 
cell type may be the best tool to use in analyzing why the integrin levels drop with 
immortalization and transformation events.  The seven GBM cell lines were further 
characterized to determine the levels of these proteins on the cell surface.  This is 
important because a difference in total αvβ8 from what is expressed on the surface 
could indicate defects in integrin transport and blur the conclusions that could be 
drawn from the hypothesis.  However, it was determined that total protein levels and 
cell surface levels aligned; indicating that when the integrin is knocked down the 
surface expression is knocked down.  Cell lines that were low in total β8 also had 
low expression on the cell surface.  This allows us to hypothesize that cell lines with 
low endogenous levels of the integrin also have low levels of TGFβ activation, 
leading to different behaviors. 
 As angiogenic phenotypes were being discovered by Dr. Tchaicha it 
was hypothesized that VEGF levels may be influenced by integrin levels which 
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could further influence invasiveness.  With this in mind a cell line with low 
endogenous β8 levels was chosen to check for basal VEGF expression and this cell 
line was over-expressed with β8 to record any influence (Figure 5A).  This led to an 
increase in VEGF being secreted from the cells.  This difference was so large that 
multiple clones were generated and the assay repeated many times.  Additionally it 
was noticed that the cells were much longer when β8 was overexpressed (data not 
shown).  This is in conflict with out hypothesis that low β8 leads to more angiogenic 
tumors.  It would be predicted that low levels of the integrin in vitro would have high 
levels of VEGF to correlate with the large amount of vascularization seen in the in 
vivo tumors.  However, it is interesting that this trend was not seen in LN229 and 
SNB-19 cells with β8shRNA, indicating there may be a factor exclusive to U87 cells 
that allows for this sensitivity.  However, this statement is hard to claim because 
THA cells with β8shRNA showed ~60% less VEGF is secreted following knockdown 
of the integrin (Figure 5).  This suggests that the results seen may not be the result 
of differences in cell type, but as a different in in vitro vs. in vivo.  It is possible that 
communication with another cell type or the stroma of the tumor is influencing the 
signaling pathway in a way that VEGF is upregulated when the integrin is knocked 
down in vivo.  
 As previously mentioned, β8 was knocked down in LN229 and SNB-19 
cell lines, which normally express high levels of the integrin.  These utilized 
bicistronic expression of GFP and β8shRNA which allows for modulation of β8 
levels by Fluorescence Activated Cell Sorting (FACS).  From here the best β8 and 
αv targeting shRNAs were determined and chosen for further experiments.  An in-
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vitro growth assay was performed to determine potential growth differences with the 
integrin knocked down (Figure 6C and 7B).  There were no growth differences 
between non-targeting and β8 targeting shRNA; however this was not true for 
αvshRNA.  Cells with αv knocked down die after the first attempt at passaging or if 
left to grow unpassaged.  This indicated the need for αv in cell survival.  If 
trypsinized they would not adhere to a new culture dish, also indicating a disruption 
in adhesion.  The need for αv for adhesion and survival was also seen with 
αvsiRNA (data not shown).  For these reasons pLB-αvshRNA LN229 and SNB19 
cells were not pursued for further in-vitro work.  However, it remains to be seen 
whether αv integrin is required for in-vivo cell survival.  Since knocking down β8 did 
not results in a difference it is likely that the cause is one of the other integrins that 
associates with αv.  This may be αvβ3 or αvβ8.  It also possible that no single 
integrin is responsible and knocking down multiple integrins is required for this 
effect in cell survival to occur.  Additionally, β8 knockdown declined in LN229 and 
SNB-19 cells as they were passaged (data not show).  Therefore consideration was 
taken to use cells only a few passages after sorting. 
 In contrast to human GBM cells, αv-/- mouse transformed astrocytes 
(mTA) are able to adhere.  Both of these cell types were analyzed by migration 
assay.  While WT cells filled the wound αv-/- mTA cells did not fill it at all.  This 
appears as though the cells do not migrate whatsoever (Figure 8 and 9).  The 
striking difference can be attributed to αv-/- cells having no αv-associated integrin 
pairs forming, rendering their signaling and adhesion less functional.  Further 
investigation though proved that the cells were not stopping all together, but were 
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just not moving across the wound region (data not shown).  The cells were still 
motile as they move up and down the scratch region.  These cells were also 
allowed to grow with a scratch region present until they became over confluent and 
died.  They still would not cross the scratch.  Though real time video capture cannot 
be displayed Figure 9 best represents the pattern of cells just after the scratch is 
made.  Note the original scratch is not a smooth line (Figure 9).  A rescue 
experiment was then attempted to see whether WT mTA cells could rescue the 
migration defect seen when αv is knocked out.  It was anticipated that the inability of 
αv-/- mTAs to activate TGFβ could be rescued by allowing WT cells to activate it.  To 
distinguish between cells the WT and αv-/- mTAs were given stably expressing RFP 
and GFP, respectively.  After imaging separately to confirm the phenotypes while 
expressing the GFP and RFP proteins, the cells were mixed in a 50:50 ratio and 
then scratched and imaged.  This revealed not only that WT cells could not rescue 
the knockouts, but they could prevent the WT cells from moving into the wound 
region.  While WT cell migration into the scratch region was not 100% it was 
severely disrupted (Figure 10).  Additionally it could be seen that an occasional αv-/- 
cell could move into the scratch region but only so long as they were adhered to a 
WT cell.  This suggests they had not lost all adhesive function as other cells could 
adhere to them.  This is interesting because the knockout cells are able to adhere to 
other cell types and to the surface of the dish, yet do not fill the wound.  Additionally 
exogenous active-TGFβ was added to these cells to see if the phenotype could be 
rescued, but this was not the case (data not shown).  The scratch experiment was 
also duplicated with 293T cells stably expressing GFP.  This non-astrocytic cell line 
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does not express β8 yet is able to migrate to fill in a scratch (data not shown).  
When mixed, it was seen that the αv-/- mTAs also inhibited the 293T cells from 
crossing into the scratch region.  This suggests that regardless of the whether a cell 
is of astrocytic origin αv-/- mTAs would be able to inhibit their migration.  This was 
the first evidence that I came across that suggests behavior of a second pathway 
that is independent of TGFβ activation.  One possibility is that there are secreted 
factors the αv-/- mTAs secrete that inhibit invasiveness.  This hypothesis was initially 
tested by taking media conditioned by αv-/- mTAs and placing it onto WT mTAs 
before conducting a scratch assay.  This however did not result in a rescue of the 
phenotype (data not shown).  If secreted factors did not alter the migration of the 
cells it was next thought that there may be a second mechanism that is independent 
of TGFβ activation.  Since TGFβ activation was known to be taking place through 
the extracellular portion of β8 it was predicted that the cytoplasmic tail of the integrin 
was likely to be playing a role.  Additionally, it may be possible that knocking out αv 
results in transcriptional differences that alter the expression of cell adhesion 
molecules such as cadherins.  In the same line of thought it may also be possible 
that knocking out αv associated integrins results in a different expression of 
unknown αv-associating adhesion molecules.  This might be tested by utilizing 
electric cell-substrate impedance sensing (ECIS) instrumentation.  This consists of 
electrode arrays of gold with a surface area for the cells to attach.  This allow for the 
resistance of cells on the tissue culture grade surface to be recorded.  Changes can 
be measured between cell types with those that have high resistance having more 
cell-cell contacts.  Additionally, these interactions can be distinguished from cell-
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ECM contacts for more specific characterization.  One potential mechanism might 
involve the integrins altering the recycling of cadherins(143).  It may be possible that 
the αv associated integrins can signal through Src or integrin-linked kinase could 
upregulate the transcriptional repressors SLUG, SNAIL, and Src-family kinase to 
prevent the transcription of E-cadherin. 
 Following these mouse data a human cell line was sought.  THAs with 
and without β8 knockdown were run through a scratch assay where it was 
determined that migration decreased with loss of the integrin.  Exogenous active 
TGFβ was also added and it was seen that the phenotype could indeed be partially 
rescued (Figure 11).  With a difference in migration being noticeable with down 
regulation of β8 polarity proteins were of interest.  Therefore these THAs were 
allowed to partially migrate and then stained for actin and focal contacts.  This 
revealed that normal THAs polarize into the wound region as expected with focal 
contacts at the leading edge and actin aligned in the direction the cells move.  
However, when β8 is knocked down with shRNA this is not the case.  The cell 
contacts are on all sides of the cell and the actin shows up in a #-hashed form with 
the actin in many different directions.  These indicated a disruption in polarity 
proteins that we wished to pursue (Figure 12).            
 Following a discovery of this role in migration effort was made to 
determine if these findings extended into in vitro invasion assays, something more 
closely mimicking the brain.  First primary mouse astrocytes were examined by 
invasion assay.  Here it was seen that when β8 is knocked out the cells invade 
about 40% less than WT cells.  Additionally, when αv is knocked out, invasion is 
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almost entirely stopped (Figure 14A).  Similar results were seen with transformed 
mouse astrocytes.  When β8 was not present in the cells invasion dropped by over 
50%, and it dropped over 95% when there were no αv-associated integrin pairs 
present (Figure 13B).  This defect in invasion could be rescued by overexpressing 
β8 in β8-/- mTAs where it was seen that these cells invade about 60% faster than 
mock transfected β8-/- cells (Figure 13C).  GBM cell lines were then analyzed.  
SNB-19 cells with β8siRNA was compared to scrambled siRNAs  where it was seen 
that silencing integrin expression reduced invasion by about 50% (Figure 14A and 
14B).  A similar 50% reduction in invasiveness was seen in LN229 cells treated with 
β8siRNA (Figure 14 C and D).  This was taken a step further with the use of a 
specific shRNA as opposed to the pool of siRNAs being used.  LN229 and SNB-19 
cells were stably transfected with β8shRNA and it was also seen that this reduced 
their invasiveness by about 65% and 55%, respectively (Figure 15A and 15B).  
Additionally two more alternative β8shRNAs were placed into LN229 cells where it 
was seen that these less efficient shRNAs were able to reduce invasiveness by 
about 40% each (Figure 16B).  THAs were also checked for their response to a 
drop in β8 expression.  They were given the same shRNA used with LN229 and 
SNB-19 cells , which significantly knocked the integrin down, resulting in about 80% 
reduction in invasiveness (Figure 17B).  Here we see that in primary and 
transformed mouse astrocytes with the integrin knocked out as well as in 
transformed human astrocytes and GBM cell lines with the integrin knocked down 
(with both siRNA and multiple shRNAs) that β8 integrin reduces in vitro 
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invasiveness.  Through these experiments we can reasonably state that β8 plays a 
major role in in vitro and warrants in vivo investigation.  
 Following these results the role of extracellular TGFβ signaling was 
probed.  First it was determined that knocking out/down the integrin with shRNA 
reduces its total expression as well as its expression on the cell surface.  WT and 
β8-/- mTAs were examined and shown to have no β8 expression on the cell surface.  
SNB-19 and LN229 cells with β8shRNA were shown to have reduced expression of 
the integrin on their cell surface when it is knocked down (Figure 18B and 18C).  
Additionally, when LN229 cells were biotinylated and αv was pulled down, a 
reduced size band was seen at the 100kDA mark.  This is the same weight as β3, 
β5, and β5.  However, since this band weakened significantly from the NTshRNA 
cells it is likely that β8 is the main integrin present. 
 With the knowledge that β8 surface expression was decreased in cells 
with β8 knocked down, the effect of extracellular TGFβ activation was analyzed.  To 
accomplish this methods were explored to interrupt SMAD signaling downstream of 
the TGFβ receptor.  This involved targeting TGFβ Receptor I and TGFβ itself.  A 
monoclonal antibody specific for TGFβ was shown to be able to bind to active TGFβ 
and prevent its ability to induce downstream SMAD3 phosphorylation (Figure 18D).  
A small molecule inhibitor was used to target TGFβRI, which is required to pair with 
TGFβRII to induce downstream SMAD signaling (Figure 18E).  When active TGFβ 
binds to the TGFβ receptor, SMAD2 and SMAD3 are normally autophosphorylated.  
With the inhibitor it was seen that there was a reduction in the phosphorylation of 
these SMADs in a dose dependent manner.  These signaling disrupters were 
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subsequently shown to reduce the invasiveness of LN229 cells without affecting 
proliferation (Figure 18F and 18G).  Since β8 activates TGFβ which signals through 
the SMAD receptors this was expected.  Additionally a third target, SMAD4 was hit 
with shRNA (Figure 18I).  After SMAD2 and SMAD3 are autophosphorylated, they 
are translocated to the nucleus by SMAD4.  When the Smads were phosphorylated 
they were not able to be transported into the nucleus by Smad4 when the shRNA 
was added (Figure 18I).  This led to a 50% reduction in invasiveness for SNB19 
cells and about a 60% reduction in in vitro invasiveness for THAs (Figure 18J and 
18K).  Despite the drop in invasiveness correlating with the drops when β8 is 
knocked down in these cells, it is still possible that alternative integrins could be 
responsible for a percentage of the TGFβ activation.  While I recognize that these 
unknown integrins may be responsible for residual TGFβ activation, β8 is the major 
integrin in TGFβ signaling (Figure 18H). 
 Taken together these data indicate that αvβ8 is an important player in 
human GBM invasiveness when analyzed from an in-vitro perspective.  This integrin 
is responsible for translating ECM cues, that is inactive-TGFβ, into signals read by 
GBM cells and likely other cell types such as endothelial cells in the tumor niche.     
 
 
 
 
 
 
 102 
 
Chapter 4: 
αvβ8 Intracellular Signaling: A Novel Mechanism of αvβ8 Cytoplasmic Tail 
Signaling and its Role in Glioma GTPase-Mediated Invasiveness. 
 
 
Introduction: 
 In this chapter we extended our studies of αvβ8 integrin from in-vitro 
extracellular adhesion studies to intracellular signaling roles that include in-vivo 
results.  Previously we saw changes in polarity (Figure 12).  Here were chose to 
pursued this phenotype and examined the activities of common polarity proteins 
Rac1, Cdc42, and RhoA.  Additionally, a previous report has shown that the 
cytoplasmic tail of β8 may bind to Rho GDI-1.  However, this system was artificial as 
it used a chimeric IL-2R/β8 to see if GDI bound.  Despite this though, it is an 
attractive possibility that the integrin may be binding to this GDI which could signal 
to a GTPase and influence cell polarity.  GDIs, or GDP dissociation inhibitors, inhibit 
the dissociation of GDP from GTPases.  This allows them to regulate the GDP-GTP 
exchange reactions required for GTPase function and thus cell motility.  
Additionally, with only in-vitro previous wor, here we seek answers that can be given 
to us in an in-vivo context.  Through this study we hope to better understand how 
changes in β8 levels can influence the invasiveness of GBM cells and hone in on 
what role it may be playing in patients.  
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Integrin β8 suppresses Rac1 and Cdc42 GTPase activity 
 LN229 cells were treated with the siRNA previously discussed (Figure 14C) 
and checked for PAK1 phosphorylation (Figure 19A).  It was seen that knocking 
down the β8 integrin increased PAK1 phosphorylation, a readout for GTPase 
activity.  This same lysate was used to also check RAC1, Cdc42, and RhoA basal 
levels and activation state.  It was seen that Rac1 and Cdc42 are activated when 
the integrin is knocked down, however the RhoA activation state remains the same 
(Figure 19A).  Additionally, LN229 cells had β8 knocked down using two separate 
shRNAs (Figure 19B).  This also showed that PAK1 phosphorylation increases 
when the integrin is knocked down.  Β8 knockout transformed mouse astrocytes 
were also analyzed for Rac1, Cdc42, RhoA, and PAK1 activity.  It was also seen 
here that the complete loss of β8 results in an increase in Rac1 activity (Figure 
19C), and Cdc42 activity (Figure 19D).  RhoA levels remained unchanged (data not 
shown) and PAK1 was phosphorylated (Figure 19E).  Previously described β8-/- 
cells were transfected to over-express β8 (Figure 5A) and checked for their 
potential to activate Rac1 and phosphorylated PAK1.  It was seen that expressing 
β8 in cells with it knocked out resulted in rescue with PAK1 phosphorylation and 
Rac1 activity both decreasing.          
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  Figure 19. 
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Figure 19. Pak1 is Phosphorylated and Rac1 and Cdc42 are Activated in a β8 
Dependent Manner 
(A) LN229 cells treated with non-targeting and β8 targeting siRNA were 
examined by western blot for PAK1 phosphorylation and total PAK.  They 
were also checked for RAC1, Cdc42, and RhoA activation.  Note the increased 
levels of phosphorylated PAK1, active Rac1, and active Cdc42.  The same 
siRNAs were used in figure 14C.  (B) LN229 cells with β8 knocked down using 
two different shRNAs.  Note the increased PAK1 phosphorylation when less 
integrin is present.   WT and β8-/- transformed mouse astrocytes were 
analyzed for (C) Rac1 activation, (D) Cdc42 activation, and (E) PAK1 
phosphorylation.  Β8-/- transformed mouse astrocytes were over-expressed 
with β8 and analyzed for (F) Rac1 activation and (G) PAK1 phosphorylation.          
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GDP Dissociation Inhibitor (GDI) Plays a Role in GTPase Activation and GBM 
Invasion  
 Human GBM cell lines LN229 and SNB-19 were analyzed by western blot for 
Rho GDI-1 and Rho GDI-2 expression.  It was determined that all of these cell lines 
expressed these GDIs and this expression was not affected by altering the level of 
integrin β8 (Figure 20A).  LN229 cells were then transfected with GDI1 targeting 
siRNA.  When GDI1 was knocked down no effect was seen on expression levels of 
β8.  Additionally, when GDI1 was knocked down PAK-1 phosphorylation was up-
regulated.  Rac1 and Cdc42 were also hyper activated when compared with the 
control, non-targeting siRNA cells that had endogenous expression levels of GDI-1 
(Figure 20B).  This also corresponded with invasive characteristics.  When GDI-1 
was knocked down by siRNA in LN229 cells they became less invasive (Figure 
20C).  This was also seen in SNB-19 cells.  The same Rho GDI-1 siRNA was used 
to knock down the GDI and the invasiveness of the cells significantly decreased 
(Figure 20D and 20E).  
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Figure 20. 
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Figure 20. Loss of Rho GDI-1 Activates Rac1 and Cdc42, Phosphorylates 
Pak1, and Reduces Invasiveness 
(A) LN229 and SNB-19 cells were analyzed by western blot for protein 
expression levels of Rho GDI-1 and Rho GDI-2 in cells expressing β8 targeting 
shRNA.  (B) LN229 cells were treated with Rho GDI-1 targeting siRNA and 
analyzed for GDI-1, β8, PAK1, Rac1, and Cdc42 expression as well as PAK1 
phosphorylation.  These same lysates were also checked for Rac1 and Cdc42 
activation states.  (C) LN229 cells treated with Rho GDI-1 siRNA were 
analyzed by invasion assay.  Note the decreased invasiveness of cells with 
less available GDI-1.  (D) SNB-19 cells were treated with RHO GDI-1 siRNA and 
analyzed by western blot.  (E) SNB19 cells treated with Rho GDI-1 targeting 
siRNA were ran through an invasion assay.  Note the substantial decrease in 
invasiveness that accompanies reduced Rho GDI-1 levels. 
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Constitutive Rac1 Activation Alters Cell Morphology and Reduces 
Invasiveness 
 LN229 cells were transfected with either an empty YFP construct or 
constitutively active Rac1 tagged with YFP.  This was verified by western blot.  
When blotted for Rac1, endogenous levels were seen, as well as an obvious band 
at the molecular weight corresponding to the additional 27kDa of the YFP (Figure 
21A).  These lysates were also probed for YFP.  Distinctive bands were seen 
corresponding the YFP and to YFP-Rac1 (Figure 21B).  Upon transfecting it was 
observed that efficiency was not 100%.  The cells that were transfected with the 
empty YFP construct maintained their elongated morphology.  The cells with the 
YFP tagged constitutively active Rac1 became flattened while the untransfected 
non-yellow cells in the same dish were still elongated (Figure 21C).  This is more 
obvious at higher magnification (Figure 21D).  These cells were sorted for YFP and 
then run through an invasion assay.  It was seen that 50% fewer cells constitutively 
active Rac1 cells invaded compared to those expressing the empty-YFP construct 
(Figure 21E).  Additionally, after the cells invaded through the membrane they were 
imaged before the membrane was stained and counted.  The cells with empty-YFP 
invaded through as yellow cells.  The YFP-Rac1 cells that invaded through were 
weakly expressing YFP (Figure 21F).  As YFP expression is tied to the amount of 
active Rac1 in these cells, this suggests that the cells with higher expression of 
constitutively active Rac1 did not invade.   
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Figure 21. 
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Figure 21. Hyperactive Rac1 Induces Morphological changes and Reduces 
Invasion in LN229 GBM Cells 
(A) LN229 cells were transfected with an empty YFP or a constitutively active 
Rac1 tagged with YFP.  Western blot was used to verify Rac1 expression and 
also (B) YFP expression.  (C) LN229 cells transfected with YFP and YFP-Rac1 
were imaged 48 hours after transfection.  The top panels show with bright-
field and YFP images over layed.  The bottom panels show just YFP.  (D) 
LN229 cells transfected with YFP and YFP-Rac1 were imaged at a high 
magnification with the YFP filter.  Note the elongated cells with the empty 
construct and the flattened morphology of those expressing constitutively 
active Rac1.  Scale bar 60µm.  (E) Sorted cells were run through an invasion 
assay.  Note the decrease in invasiveness when Rac1 in constitutively active.  
(F) After 24 hours the invasion assay membranes were imaged.  The top 
panels show bright field overlaying YFP and the bottom panels display YFP 
only.  Note the weak expression of YFP among cells that invaded expressing 
active Rac1.     
LN229-pEYFP LN229-Rac1 L61
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Rho GDI-1 Binds to Integrin β8 
 LN229 cells were transfected with plasmids expressing GFP or GFP tagged 
Rho GDI-1.  Additionally, one set of GRP-RhoGDI1 was treated with β8 targeting 
siRNA.  These were then immunoprecipitated with mouse anti-GFP antibody and 
blotted with rabbit anti-β8 (top) or rabbit anti-GFP (bottom) antibodies (Figure 22A).  
Here it can be seen that Rho GDI-1 binds to integrin β8 and when the integrin is 
knocked down, less GDI can be pulled down by immunoprecipitation.  The opposite 
immunoprecipitation was then carried out on these cells.  They were 
immunoprecipitated with goat anti-β8 and blotted with mouse anti-GFP and rabbit 
anti-β8 (Figure 22B).  When β8 was pulled down GFP can be seen just below the 
heavy chain.  This indicates Rho GDI-1 binds to integrin β8. 
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Figure 22. 
 
 
 
 
 
Figure 22. Rho GDI-1 Co-Immunoprecipitates with β8 in LN229 GBM Cells 
(A) LN229 cells were transfected with either GFP or GFP tagged Rho GDI-1.  
They were then immunoprecipitated with GFP and blotted for GFP or β8.  
Additionally, one set of cells was treated with β8 targeting siRNA.  Note the 
A 
B 
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band indicated Rho GDI-1 is being pulled down and how this is reduced by 
reducing β8 expression.  (B) Empty-GFP and GFP-RhoGDI1 cells were 
immunoprecipitated with β8 and blotted for either GFP.  Note the band 
corresponding to GFP-RhoGDI1 being pulled down.  The bottom blot shows 
immunoprecipitation with β8 and then blotting with β8.  This reveals that β8 is 
indeed being pulled down in the first step.  
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Rho GDI1 Binds to the Cytoplasmic Tail of Integrin β8 
 293T cells with no endogenous β8 were infected with lentivirus to express full 
length or truncated β8.  These were verified by blotting with a cytoplasmic β8 
specific antibody and an antibody targeting the extracellular portion (Figure 23A).  
When the extracellular β8 targeting antibody is used it can be seen that the 
truncated β8 expressed in the cells is a lower molecular weight than the full length.  
These cells were then biotinylated and immunoprecipitated with αv.  The present 
band indicates that truncated β8 is still able to pair with its αv subunit (Figure 23B).  
Additionally, the full length and truncated β8 were placed into β8-/- transformed 
mouse astrocytes.  This was verified by western blot where again the truncated β8 
is seen to have a lower molecular weight as would be expected (Figure 23C).  
Additionally, Rac1 activation and Pak1 phosphorylation were checked to see if the 
signaling could be rescued.  β8-/- cells with truncated β8 were seen to have similar 
levels of Rac1 activation to those without the integrin (Mock) (Figure 21C).  
However, cells with full length β8 had significantly less Rac1 activation.  A similar 
trend was seen for Pak1 as cells with full length β8 are less phosphorylated than 
those with truncated β8 or no β8 (Figure 21C).  These cells were then run through 
an invasion assay where it was seen that cells with no β8 and those with 
cytoplasmically truncated β8 invade at similar rates while cells with full length β8 
invade about 40% faster (figure 23D).   
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Figure 23. 
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Figure 23. Rho GDI-1 Interacts with the Cytoplasmic Tail of β8 and Mediates 
Cell Invasion 
(A) Full length and cytoplasmically truncated β8 were added to 293T cells 
which have no endogenous β8 but do have endogenous αv.  A cytoplasmic 
specific β8 antibody was used to verify expression of the full length protein 
and no expression of truncated protein.  (B) 293T cell expressing the full 
length and truncated β8 proteins were biotinylated and immunoprecipitated 
with and an-αv antibody.  Note how β8 is able to bind with 293T’s endogenous 
αv.  (C)  β8-/- cells with and without full length and truncated β8 were checked 
by western blot for β8, Rac1, and Pak1 expression.  Additionally, Pak1 
phosphorylation and Rac1 activity were also checked.  Note the low activity of 
Rac1 and the low phosphorylation of Pak1.  (D) These cells were also ran 
through an invasion assay.  Note the increased invasiveness of cells with full 
length β8 compared to those with truncated or no β8.   
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Human Patient GBMs Display High Levels of Integrin β8  
 Immunohistochemistry was performed on human GBM sections.  The 
following representative images show staining with goat IgG and goat anti-β8 
(Figure 24A and 24B).  The reactivity and specificity of the β8 antibody is evident in 
the copper toned staining (Figure 24B).  This antibody was used on tumor sections 
that also had a section of normal non-tumorigenic brain (Figure 24C).  The top 
panel shows a low level of β8 expression while the bottom panel shows a tumor 
margin with extremely high levels within the tumor.   Four human GBM sections 
from the center of the tumor were also stained (Figure 24D).  These reveal the large 
amount of integrin β8 within the tumor and the lack of β8 in intratumoral blood 
vessels.  
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Figure 24. 
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Figure 24. Human Patient GBM Tumors Express High Levels of β8 
Immunohistochemistry performed on human GBM samples with (A) goat IgG 
and (B) a goat anti-β8 antibody.  (C) Two different human GBM sections were 
stained that contained normal non-tumorigenic tissue.  The lower panel 
shows a tumor margin.  (D) Immunohistochemistry was carried out with anti-
β8 antibody on four human GBMs section taken from the center of the tumor.  
Note the high level of β8 within the tumor.  Scale bar 200µm. 
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β8 Integrin Levels Direct Human GBM Cell Invasiveness and PAK1 
Phosphorylation In-Vivo  
 LN229 GBM cells with either non-targeting shRNA or β8shRNA previously 
described (Figure 6) were stereotactically injected into the striatum of nude mice 
and sacrificed after 7 weeks.  The brains were sectioned and H&E stained (Figure 
25A).  The tumors originating from control LN229 cells were very invasive, with 
many individual cells moving away from the primary tumor mass, while those with 
β8 knocked down lost invasiveness (these statements were verified by a pathologist 
specializing in brain tumors).  Tumors with β8 knocked down were also much larger.  
This was quantified by measuring the two-dimensional surface area (Figure 25B).  
Immunofluorescence was also carried out on these tumors with an anti-GFP 
antibody to show tumor expression within the mouse brain (Figure 25C and 25D).  
In the bottom panel the tumor margin of the tumor with β8 knocked down is very 
distinct while in the upper panel the LN229 tumor with high levels of the integrin is 
very invasive.  Additionally, the tumors were stained for KI-67 as it is known to be a 
marker for proliferation.  The larger LN229-β8shRNA tumors did not show more KI-
67 staining than the LN229-NTshRNA tumors (Figure 25E and 25F).  These tumors 
were also doubled stained for GFP and pPAK1.  It can be seen that invasive LN229 
NT-shRNA tumor cells have little to no pPAK1 (Figure 25G).  Alternatively, the non-
invasive LN229 β8shRNA tumor cells have high levels of phosphorylated PAK1 
(Figure 25H).  These results correspond to those seen in-vivo (Figure 14D and 
19B).         
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Figure 25. 
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Figure 25. αvβ8 Mediates Invasion and Pak1 Phosphorylation in an Orthotopic 
Mouse Model 
(A) LN229 human GBM cells expressing either non-targeting shRNA or 
β8shRNA were injected into nude mice, sacrificed, perfused, sectioned, and 
H&E stained.  (B) The surface area of the stained H&E sections was 
quantified. (C) H&E staining of LN229 non-targeting shRNA tumor (top) and 
LN229 β8shRNA tumor (bottom).  (D) A different section of the same tumor 
shown in Figure C is shown that has been immunofluorescently GFP stained 
to reveal the tumor cells.  Note the increased invasiveness of the β8shRNA 
containing tumors.  (E) LN229-NTshRNA and (F) LN229-β8shRNA tumor were 
stained for KI-67.  Note the larger tumor does not have more KI-67 staining.  
(G) LN229 NT-shRNA and (H) LN229 β8shRNA sections were stained with both 
anti-GFP and anti-pPAK1 antibodies.  High resolution of (I) GFP and (J) pPAK 
staining in pLB-LN229 tumors.  Note the lack of pPAK1 in invading LN229 NT-
shRNA tumor cells.   
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Discussion 
 LN229 GBM cells were treated with scrambled, non-targeting or β8 targeting 
siRNA for analysis of PAK phosphorylation.  p21 activated kinase-1 (PAK1) is 
autophosphorylated following binding to GTP-bound Rac1 or Cdc42.  Thus PAK1 
phosphorylation is used as a read out for Rac1 and Cdc42 activity.  It was seen that 
when the integrin is knocked down more Pak1 is phosphorylated.  Following this the 
activity states of three GTPases were checked for their activity.  It was seen that 
both Rac1 and Cdc42 are activated when the integrin is knocked down, while the 
level of their protein expression does not change.  Additionally, RhoA was checked 
which had no excess activity as measured by GTP bound levels (Figure 19A).  As 
PAK1 is not known to be phosphorylated by active RhoA this fits with the previous 
results.  siRNA experiments were preferred because they offered us better 
knockdown than shRNAs.  However, I also checked two different β8shRNAs in 
LN229 cells where it was also shown that their levels of PAK phosphorylation go up 
significantly when the integrin in knocked down (Figure 19B).  This trend was also 
seen in transformed mouse astrocytes where those with β8 knocked out had 
increased phosphorylation of PAK1 and increased levels of active Rac1 and Cdc42 
(Figure 19C, 19D, and 19E).  This signaling was also rescued when β8 was over 
expressed in β8-/- cells as PAK1 phosphorylation and Rac1 activation significantly 
decreased (Figure 19F and 19G). 
 It was previously reported that GDI1 could bind to the cytoplasmic tail of β8 
in an artificial system(144).  We therefore decided to pursue a GDI link.  First we 
established that both Rho GDI-1 (GDIα or Rho GDI) and Rho GDI-2 (Rho GDIβ or 
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D4-GDI or Ly-GDI) are present in both LN229 and SNB-19 GBM cell lines.  
Additionally, the levels of GDI are not influenced by the levels of β8 (Figure 20A).  
Following this we knocked down Rho GDI-1 with siRNA.  This revealed that GDI 
levels can influence Rac1 and Cdc42 activation states.  PAK1 was phosphorylated 
and Rac1 and Cdc42 were activated in cells with less Rho GDI-1 (Figure 20B).  This 
verified the known function of GDIs.  GDP dissociation inhibitors (GDIs) work by 
binding to GDP bound Rho proteins.  This GDP bound version is the inactive state 
while the protein become active when they are bound to GTP.  By bind to GDP 
bound Rho proteins, the GDIs are able to hold them in their inactive state.  
However, when they are released these proteins are free to bind to GTP and 
become activated.  The increase in PAK1 phosphorylation and the activation of 
Rac1 and Cdc42 Rho proteins when the GDI1 siRNA was present mimicked the 
signaling seen when the integrin is knocked down.  When this GDI was knocked 
down in LN229 cells they also saw a reduction in invasiveness (Figure 20C).  This 
increase in PAK1 phosphorylation and reduction in invasiveness was also seen 
when the GDI was knocked down in SNB-19 cells with ~75% reduction in 
invasiveness (Figure 20E). 
 As manipulation of GDI and β8 integrin levels were seen to alter Rac1 
activation we then looked at Rac1 more closely.  To do this we transfected YFP 
tagged constitutively active Rac1 into LN229 cells.  When the expression was 
verified by anti-Rac1 the YFP levels were also checked (Figure 21A).  This showed 
that the tagged active Rac1 was expressed at similar levels to that of the empty 
YFP construct (Figure 21B).  Upon transfection an interesting phenotype was noted.  
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The YFP-positive active Rac1 cells appeared much flatter than the control cells.  
When checked under a fluorescent microscope this change was obvious as all of 
the YFP+ cells had a flattened morphology while untransfected cells in the same 
culture appeared elongated like the control cells (Figure 21C).  This is very apparent 
at high magnification where it can be seen that the cells are trying move in all 
directions at once; the result being a flattened morphology (Figure 21D).  This would 
explain why the THA cells had focal contacts around all sides of the cell and had 
actin aligned in multiple directions (Figure 12).  These cells were then sorted by 
FACS for YFP and run through an invasion assay where about a 50% drop in 
invasiveness was seen (Figure 21E).  Additionally, before the cells were stained for 
quantification they were checked under a fluorescent microscope (Figure 21F).  It 
was seen that the few LN229 cells that did migrate through were poorly expressing 
the YFP meaning they had lower levels of constitutively active Rac1.   While the 
control cells that migrated through expressed much higher levels of YFP.  Since 
both cell types started out with similar levels of YFP intensity this suggests that the 
constitutively active Rac1 cells were not invading through to the bottom of the 
chamber while those with less of the construct were.  Therefore it is likely that cells 
that have more activated Rac1 are less invasive. 
 To connect the defects found for active Rac1 and β8 we looked at the ability 
of Rho GDI-1 to bind to the cytoplasmic tail of β8.  As was previously mentioned, 
this interaction was detected using an artificial system.  This included making a 
chimera protein of Interleukin-2 (IL-2) with a β8 cytoplasmic tail attached and 
transfecting it into human embryonic kidney 293T cells.  The reason this was done 
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was due the lack of quality antibodies.  With a chimeric protein they were able to 
target the IL-2 with and antibody and blot for the GDI.  Instead of this artificial 
system I decided to look at this interaction in LN229 cells.  The same cells I used for 
a majority of the in vitro and in vivo work.  Due to antibody constraints this was first 
attempted with a GFP-RhoGDI1 construct.  Rho GDI-1 was seen to bind to β8, and 
when the integrin was knocked down with siRNA the binding signal also decreased 
(Figure 22A and 22B).  A GFP-GDI2 construct was also used, however no β8-GDI2 
interaction was found (data not shown).  These results were very interesting as the 
cytoplasmic tail of β8 shows little homology to the cytoplasmic tails of the β3 and β5 
integrins.  In the future a more definitive statement could be concluded regarding 
other integrins pairing with GDI1 by performing immunoprecipitations in cells that 
have higher levels of these integrins and with the corresponding antibodies.  
However since the predominant integrin expressed in all of the astrocytes analyzed 
is β8, its signaling in the context of a whole cell would like dominate any small 
contributions by the β3 and β5 integrins.     
 To strengthen the conclusion we utilized constructs with the cytoplasmic tail 
of the integrin truncated.  Full length and truncated β8 was placed into 293T cells, 
which have no endogenous β8 expression, to verify its expression (Figure 23A).  
Additionally it was seen that the truncated β8 is still able to pair with αv by 
biotinylation (Figure 23B).  This is important because the sequences that interact 
between αv and β8 are not known and removing the cytoplasmic tail could cause 
them to not form a pair.  However, the biotinylation allows one to verify that αv and 
β8 are pairing on the cell surface.  The constructs were then placed into β8-/- mTAs 
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to verify the role of the cytoplasmic tail.  Indeed it was the case that the knockout 
cells and those with the cytoplasmic tail truncated lacked the invasive phenotype 
seen in GBMs.  Addition of the cytoplasmic tail increased in-vitro invasiveness by 
about 40% meaning it is required for the downstream signaling events to take place 
(Figure 23D). 
 Despite a large amount of evidence of β8’s role for invasiveness in-vitro, in-
vivo work was sought for greater relevancy.  Examining human GBMs by 
immunohistochemistry we were able to see how levels of the integrin vary between 
tumors but in general are high, just as seen in cell lines (Figure 24D and 4).  The 
cell line used in most of the in vitro experiments, LN229, was used for animal 
studies.  The previously described LN229-β8shRNA cells were seen to be incredibly 
non-invasive when injected into the mouse brain (Figure 15B and 25A).  The control 
tumors were very invasive while those with the integrin knocked down were not 
invasive at all (verified by a pathologist).  These knockdown tumors were also much 
larger (Figure 25).  Staining for their GFP expression allowed for a better 
visualization of how invasive these cells really are (Figure 25D).  As a size 
difference was apparent these were checked by KI-67 staining (Figure 25E and 
25F).  As a weak signal suggests slower proliferation, the β8shRNA tumors are not 
seen to be more proliferative than the control tumors, just as the case in-vitro 
(Figure 6C).  Additionally, these tumors were stained for pPAK1 as a read out for 
Rac1 and Cdc42 activity.  It is clear that pPAK levels are high in the control tumors 
while it is low in tumors with the integrin knocked down (Figure 25H and 25G).  This 
is more apparent at higher magnification as the GFP+ tumor cells overlay exactly 
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with areas of the brain that have little to no PAK phosphorylation (Figure 25I and 
25J).  These in vivo finding suggest that the mechanism found in vitro is also taking 
place in vivo.  That being GDI-1 bind to the cytoplasmic tail of β8, prevents Rac1 
and Cdc42 from being activating and PAK1 from being phosphorylated.  However, 
when the integrin is knocked down or knocked out there is no β8 for the GDI-1 to 
bind to.  In this situation β8 is not able to increase the affinity for GDI-1 for GDP 
bound Cdc42 or Rac1.  This leaves these be more easily converted to GTP and 
activated which leads to a loss of their invasiveness.  In the future this model could 
be more closely explored with a FRET biosensor.  CFP could be bound to GDI-1 
and YFP to β8.  These could then be imaged with a live imaging microscope that 
could excite the CYP.  The emission wavelengths could then be read to watch the 
GDI1-β8 interaction in real time.  When the CFP emission is read there is no 
interaction.  However the emission wavelength from CFP can excite YFP if a 
change in protein conformation takes place.  Therefore when GDI-1 binds to β8 the 
YFP fluorophore would be excited and emit a wavelength consistent with YFP only, 
revealing a β8 induced conformational change in GDI-1.  This could also be 
repeated by placing the YFP onto the Rac1 (or Cdc42) instead of the β8 to record 
changes in the GDI1-Rac1GDP conformation induced by integrin β8.           
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Chapter 5: 
Conclusion 
 This investigation is the first to link αvβ8 to the invasive pathologies 
associated with GBMs and  identify a clear mechanism stemming from the 
cytoplasmic tail of the β8 subunit.  Several key observations were made and are 
detailed below: 
 
1.  Overexpression of β8 in GBM U87 cells and knockdown of β8 in THAs correlates 
with VEGF expression. 
2. αv-/- primary and transformed mouse astrocytes have significantly inhibited 
migration and invasiveness that is not rescued by WT cell derived TGFβ activation. 
3.  Knocking down β8 in human GBM tumor cells and knocking it out in primary and 
transformed mouse astrocytes inhibits their invasive potential which can be rescued 
with over expression of β8. 
4.  Inhibiting TGFβ signaling reduces SMAD2/3 phosphorylation and invasiveness. 
5. Silencing β8 and GDI causes Rac1 and Cdc2 activation and reduces 
invasiveness in-vitro.  Re-expressing β8 in knockout cells knocks down Rac1 
activation and PAK1 phosphorylation. 
6.  Silencing β8 causes PAK1 phosphorylation in-vitro and in-vivo. 
 7. Constitutively active Rac1 induces a flattened morphology and reduces 
invasiveness. 
8.  Rho GDI-1 binds to the cytoplasmic tail of β8. 
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9. Silencing β8 in GBM cells reduces invasiveness but increases tumor size in an 
orthotopic mouse model. 
10. The β8-/- Rac1/Cdc42 signaling and invasive defect is accounted for by the loss 
of signaling through the cytoplasmic tail. 
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Chapter 6: 
Perspectives and Future Directions 
 I detail a previously unknown role for αvβ8 in GBM invasiveness.  This 
knowledge could lead to better profiling of GBM tumors which has the potential to 
allow physicians to better predict tumor behavior and adjust the treatment plan 
appropriately.  Additionally, the reported results raise several substantial curiosities 
and questions that are worthy of pursuit.    
 Among these are the possibility that β8 can function to modulate the 
invasiveness of the tumor.  If this is the case different therapies could be given to 
patients with different β8 levels.  This might mean an inhibitor of β8 could prevent 
invasiveness.  However, our lab has extensive evidence suggesting a model of 
inverse pathophysiologies.  When there is high αvβ8 the individual cells tend to be 
more invasive in-vitro and as a tumor function more invasively in-vivo.  While when 
there are low levels of the integrin the tumors are more angiogenic.  At face value 
this would present an interesting paradox for clinicians; too much β8 and the tumor 
cannot be caught with a scalpel, too little β8 and you feed the tumor.  However, this 
may be attenuated if the pathways responsible for each phenotype can be 
independently addressed, without affecting the other.  We have previously shown 
that manipulating levels of β8 correlate with changes in the amount of VEGF 
secreted by the cell and attributed the in-vivo angiogenic phenotype to this.  If αvβ8 
signaling levels could be knocked down in a patient with an inhibitor, VEGF 
transcription and secretion will increase.  While it might be hard to directly target this 
transcription it would be feasible to reduce the function of the VEGF being secreted.  
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This could be accomplished with a VEGF blocking antibody.  Bevacizumab 
(marketed as Avastin), is a drug being explored in the clinic that does just that(121).  
Further investigation into these pathways could lead to dual treatment with the 
inhibition of β8 and VEGF. However, a pitfall to this is that while Avastin has been 
seen to decrease angiogenesis, it has also been seen to increase the invasiveness 
of the tumor(145-150).  One explanation to this is that a Bevacizumab treated tumor 
turns hypoxic as it becomes less angiogenic which is known to increase p38 
activation.  The Nishimura group has shown that p38 is directly involved in β8 
transcription and inhibiting p38 reduces integrin transcription and protein 
expression(60).  However, should this feedback mechanism be involved, excess β8 
production would have a minimal effect as the drug could easily saturate it.  A pitfall 
would be if a second mechanism, independent of β8, is activated by Bevacizumab.  
In this case the tumor would select for a population of cells that had a pro-invasive 
mechanism capable of overriding αvβ8’s effects on Rac1 and Cdc42 signaling.  This 
would result in the need for a different anti-angiogenic therapy(145,147-158). 
 Additionally, it remains to be seen whether one GTPase can override the 
activity of another, in terms of cell motility(159-162).  We have seen mechanistically 
that β8 does not control RhoA.  It may be the case that over-activating Cdc42 and 
Rac1 activity can halt invasiveness, but it not be an exclusive event.  Aberrant RhoA 
behavior may result in changes in invasiveness independent of Cdc42 and 
Rac1(162-166).  This could be addressed with dominant negative and dominant 
positive constructions.  Additionally regulatory factors may be able to overcome 
excessive GTPase activity or inactivity(167-175).  In the future it may be of interest 
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to look into GTPase-Activating Proteins (GAPs) and Guanine nucleotide Exchange 
Factors (GEFs)(176-184).  GEFs regulate GTP to GDP exchange so that the 
GTPase is bound to GTP and activated(178,180,184-190).  GAPs speed up the 
hydrolysis of GTP to GDP, allowing the removal of a phosphate and the GTPase to 
return to an inactive state(163,188,191-196).  This gives GAPs and GEFs opposing 
functions, which harmonize to allow for the normal cycle to take 
place(160,170,189,197-202).  When β8 is knocked down the activity of Cdc42 and 
Rac1 increase.  It would be interesting to know which GAPs and GEFs are 
specifically used in these pathways in GBM cells.  Once this is determined it could 
be seen if reducing the amount of GEF present would also reduce the amount of 
activation of the Cdc42 and Rac1 GTPases when β8 is knocked down.  This could 
be accomplished with siRNAs.  Conversely one would also want to analyze the 
GAP activity and see if adding a constitutively active GAP could cause the active 
GTPases to turn over much more quickly(203-207).  This would be interesting as it 
could result in much faster moving cells than the wild-type normally display.  The 
mechanisms upstream of these GAPs and GEFs could then be analyzed.  If an 
αvβ8 targeting therapy initially works and relapse to an invasive phenotype, these 
upstream pathways would likely explain resistance.  However, this would be no 
easy task as there are predicted to be between 59 and 70 proteins with RhoGAP 
domains that may be involved with Rho GTPases and an unknown number of 
GEFs, as there is no distinguishing motif(163,171,197,208-214). 
  Another intriguing possibility is that αvβ8 may be able to bind to TGFβRI or 
TGFβRII.  Pilot studies have shown that TGFβRII may co-immunoprecipitate with 
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β8 however these could not be replicated (data not shown).  It may be possible that 
the interaction is highly dynamic and responsive to other factors.  This might be 
addressed by utilizing cross-linking reagents during the procedure.  Additionally, 
one could utilize the truncated β8 construct to see if this tail is required for 
association with a TGFβ receptor.  An alternative to this would be to engineer a 
FRET biosensor by expressing Cyan Fluorescent Protein (eCFP) on the 
cytoplasmic tail of β8 and express or commercially purchase TGFβRI and TGFβRII 
with a YFP tag on their cytoplasmic domains.  This would allow for in-vitro 
characterization of this interaction as the CFP protein can excite the YFP to 
fluoresce.  Additionally, one could inject GBM cell lines with these constructs, cut a 
window into the skull and then utilize a two-photon excitation microscope to image.  
This would allow for real time in-vivo imaging of the interaction taking place and 
would lend insight into how cells with more YFP excitation behave.   
 The cytoplasmically truncated β8 construct could also be used to determine if 
the cytoplasmic tail of the integrin is responsible for up-regulation of VEGF levels.  
U87 cells over expressing V5 tagged β8 were previously seen to up regulate VEGF 
secretion.  It would be interesting to over express the non-tagged β8 or the 
truncated β8 in this cell line.  This could verify that the v5 tag is not involved in the 
increase in VEGF.  Another possibility would be to compare the β8-/- cells with the 
full length and truncated integrin.  The truncated construct could define whether the 
signaling that led to VEGF up regulation is tied to the cytoplasmic tail (and possibly 
Rac1/Cdc42 signaling) or to the extracellular portion (and possibly TGFβ dependent 
signaling).   
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 Interesting, I have also found that Cilengitide and a Cilengitide-like peptide 
may be able to bind to β8, preventing the binding of inactive-TGFβ (data not 
shown).  This result has the most potential for a low effort, high impact project.  As a 
direct protein-peptide interaction has been seen in mixing experiments, the next 
step would be to add the peptides to cells expressing robust levels of αvβ8 to 
determine the effect of this drug on Rac1 and Cdc42 activity.  It may be the case 
that these peptides are able to block TGFβ activation by the integrin and/or 
manipulate the ability of the cytoplasmic tail to bind to Rho GDI-1.  Additionally in-
vivo experiments could be done to determine if Cilengitide treatment of a β8-high 
tumor results in a similar or reduced invasive phenotype.  In parallel one could data-
mine a tissue bank of human tumors.  Should such resource be made available, 
one might select tissue samples of patients treated with Cilengitide and of patients 
treated with alternative drugs.  It would be interesting to determine if Cilengitide 
treatment of patients with β8-high tumors results in a less invasive pathology.  As a 
drug currently in Phase III clinical trials, further exploring this behavior of Cilengitide 
could lead to an immediate benefits for patients.       
 Taken together, this thesis has provided a significant advance in the 
research of integrin αvβ8.  Further exploration is recommended to fully understand 
this protein’s role in GBM invasiveness and its impact on patients. 
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